Review

Flavonoids Alleviate Peripheral Neuropathy Induced by Anticancer Drugs

Manaal Siddiqui 1,†, Basma Abdellatif 1,†, Kevin Zhai 1,*, Alena Liskova 2, Peter Kubatka 3 and Dietrich Büsselberg 1,*

1 Weill Cornell Medicine-Qatar, Education City, Qatar Foundation, Doha 24144, Qatar; mas4002@qatar-med.cornell.edu (M.S.); bwa4001@qatar-med.cornell.edu (B.A.); kez4003@qatar-med.cornell.edu (K.Z.)
2 Department of Obstetrics and Gynecology, Jessenius Faculty of Medicine, Comenius University in Bratislava, 036 01 Martin, Slovakia; liskova80@uniba.sk
3 Department of Medical Biology, Jessenius Faculty of Medicine, Comenius University in Bratislava, 036 01 Martin, Slovakia; peter.kubatka@uniba.sk
* Correspondence: dib2015@qatar-med.cornell.edu
† These authors contributed equally to the manuscript.

Citation: Siddiqui, M.; Abdellatif, B.; Zhai, K.; Liskova, A.; Kubatka, P.; Büsselberg, D. Flavonoids Alleviate Peripheral Neuropathy Induced by Anticancer Drugs. Cancers 2021, 13, 1576. https://doi.org/10.3390/cancers13071576

Academic Editors: Raffaele Capasso and Barbara Romano

Received: 17 February 2021
Accepted: 19 March 2021
Published: 29 March 2021

Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

Simple Summary: Chemotherapy-induced peripheral neuropathy (CIPN) is a debilitating condition that severely reduces the quality of life of a considerable proportion of cancer patients. There is no cure for CIPN to date. Here, we explore the potential of flavonoids as pharmacological agents in combating CIPN. Flavonoids alleviate CIPN by reducing oxidative stress, inflammation, and neuronal damage, among other mechanisms. Future research should evaluate the efficacy and side effects of flavonoids in human models of CIPN.

Abstract: Purpose: This study aimed to assess the potential of flavonoids in combating CIPN. Methods: PubMed and Google Scholar were used, and studies that investigated flavonoids in models of CIPN and models of neuropathic pain similar to CIPN were included. Only studies investigating peripheral mechanisms of CIPN were used. Results: Flavonoids inhibit several essential mechanisms of CIPN, such as proinflammatory cytokine release, astrocyte and microglial activation, oxidative stress, neuronal damage and apoptosis, mitochondrial damage, ectopic discharge, and ion channel activation. They decreased the severity of certain CIPN symptoms, such as thermal hyperalgesia and mechanical, tactile, and cold allodynia. Conclusions: Flavonoids hold immense promise in treating CIPN; thus, future research should investigate their effects in humans. Specifically, precise pharmacological mechanisms and side effects need to be elucidated in human models before clinical benefits can be achieved.

Keywords: flavonoids; CIPN; chemotherapy; peripheral neuropathy

1. The Burden of CIPN and the Hope of Flavonoids

Chemotherapy-induced peripheral neuropathy (CIPN) is a common side effect of cancer treatment with antineoplastic agents. The neurotoxic effects of anticancer drugs lead to neuropathy in about 70% (up to 90% for oxaliplatin) of cancer patients [1]. Anticancer drugs that commonly induce peripheral neuropathy include plant alkaloids (e.g., vincristine, vinorelbine, and vinblastine), taxanes (e.g., docetaxel, paclitaxel, and cabazitaxel), platinum drugs (e.g., cisplatin and carboplatin), immunomodulatory drugs (e.g. thalidomide and pomalidomide), and proteasome inhibitors (e.g., bortezomib) [2]. These drugs damage sensory, motor, and autonomic nerves through various mechanisms, resulting in neuronal degradation [1]. Existing evidence shows that these mechanisms include proinflammatory cytokine release, oxidative stress, mitochondrial damage, ion channel activation, ectopic discharge, microglial enhancement, and astrocyte activation. Besides these, other neuroinflammatory mechanisms are involved in the pathogenicity of CIPN [3–7]. Furthermore,
there is evidence of a unique pattern of central pain processing in patients with CIPN; for example, the precuneus, a region implicated in conscious pain perception, is significantly more active in people with CIPN than in normal individuals during painful stimulation. Patients with CIPN also exhibit reduced activation of the right superior frontal gyrus, an area associated with subjectively unpleasant experiences such as pain [8].

CIPN can be acute, starting days or hours after chemotherapy, or chronic, starting several months after chemotherapy [7,9]. CIPN symptoms tend to worsen over time; this phenomenon is known as the “coasting effect” [10]. Symptoms include tingling, burning, freezing, electroshock-like sensations, numbness, weakness, and pain [2,10]. These symptoms have symmetrical effects and often follow a stocking and glove distribution, affecting the extremities [1]. CIPN is a debilitating condition that interferes with daily activities, causing emotional distress and reducing the quality of life [11,12]. Since its symptoms are dose-dependent, CIPN is also the leading cause of premature chemotherapy cessation, leading to reduced life span [1,10]. Moreover, peripheral neuropathy itself is associated with all-cause mortality in adults and can therefore be used as a marker for death risk [13].

Some treatments employed to manage CIPN include steroids, antidepressants such as duloxetine, numbing medications such as lidocaine and capsaicin, and antiseizure medications such as gabapentin and pregabalin [14,15]. While opioids are prescribed for those with extraordinarily severe or chronic CIPN, this practice is discouraged by the Centers for Disease Control due to the opioid epidemic [15]. Current treatments are based on other neuropathic pain models (diabetic, herpetic, and others) and have limited efficacy in CIPN.

Furthermore, there is no evidence for the pharmacological efficacy of antiseizure and antidepressant medications in treating CIPN [15]. Duloxetine is the only nonopioid pharmacological medication with consistent efficacy [15]. Unfortunately, recent in vivo and in vitro studies on CIPN states have yielded no major pharmacological advancements. Moreover, the majority of patients with CIPN receive no medical treatment for their symptoms [16]. These factors underscore the need for standardized, reliable treatments to improve cancer patients’ quality of life. Prior studies of CIPN mechanisms need to be thoroughly re-examined in light of contemporary studies investigating treatments. One class of compounds with the potential to relieve CIPN is flavonoids.

Flavonoids are secondary plant metabolites ubiquitous in fruits, vegetables, flowers, and barks [17]. They are phenolic compounds with variously substituted three-ring structures [18]. Flavonoids exert anti-inflammatory, antioxidant, anxiolytic, neuroprotective, and anti-nociceptive properties [17], which grant alleviative effects in neuropathic pain models such as CIPN, diabetic neuropathy, and sciatic nerve chronic constriction injury [18,19]. Flavonoids’ anticancer properties depend on the previously mentioned activities and their apoptotic, anti-angiogenic effects; they also target the Warburg effect [20–22]. The neuroprotective effects of flavonoids may stem from their interference with the serotonin, dopamine, GABA, and glycine neurotransmitter (NT) pathways [18].

The flavonoid backbone consists of 15 carbon atoms arranged in the form of C6-C3-C6. Thus, it includes two benzene rings (A and B) connected by three carbon atoms, which may form a third (C) ring [17,23]. Structurally effective flavonoids consist of a catechol substructure on the A or B ring, a C3-OH group on the C ring, and an oxo group on C4. Above mentioned flavonoids’ beneficial effects are enhanced by a double bond between C2 and C3 due to planar molecule formation and increased double bond conjugation Figure 1 [23]. According to the carbon of the C ring, which is connected to the B ring and the oxidation and degrees of unsaturation of the C ring, flavonoids are classified into the following sub-groups: anthocyanins, flavanones, flavones, flavonols, flavanols, and isoflavones [17,23].
Structurally, flavones have two benzene rings linked by a heterocyclic pyrone ring (2-phenyl-chromones) [25]; essential members of this class include luteolin, apigenin, isoorientin, and icarin. Flavanones are dihydroflavones; therefore, the C ring and the bond between positions 2 and 3 are saturated [26]. Examples of flavanones are hesperetin, naringenin, silybinin, and eriodictyol. Flavanols—which include catechins and epicatechin—are the 3-hydroxy derivatives of flavanones [26]. Isoflavones have estrogenic properties and structures that include 3-phenyl-benzopyrone [27]; the main isoflavones are genistein, daidzein, biochanin A, and glycitein. Anthocyanins’ basic structural unit is the flavylium cation (2-phenylbenzopyrrolium); this confers a positive charge on the oxygen skeleton. Most anthocyanins are acylated by organic acids through ester bonds. Important group members include cyanidin, delphinidin, malvidin, and peonidin. Finally, flavonols, such as quercetin, morin, and kaempferol, have a 2-phenyl-3-hydroxy-chromone backbone; rutin is a flavonol glycoside composed of quercetin and disaccharide rutinose [28,29]. The chemical structures of flavonoid classes can be seen in Figure 1.

Several studies investigated flavonoids’ role in counteracting CIPN and reversing related oxidative stress and neuronal damage. The growing burden of CIPN and the emerging potential of flavonoids necessitate an analysis of the mechanisms by which flavonoids counter CIPN. Here, we review these mechanisms (see Figure 2) in the periphery, dorsal root ganglion, and spinal cord dorsal horn synapse, as well as in astrocytes and microglial cells.
2. Materials and Methods

PubMed and Google Scholar were searched using the following keywords: “flavonoids”, “CIPN”, “neuropathic pain”, and “peripheral neuropathy”. One hundred thirty-four results were obtained for the combination “flavonoids” AND “CIPN”, 6620 for “flavonoids” AND “neuropathic pain”, and 4909 for “flavonoids” AND “peripheral neuropathy”. We included studies that investigated the effects of flavonoids on models of CIPN, sciatic nerve chronic constriction injury (CCI), partial sciatic nerve ligation (PNL), spared nerve injury (SNI), and spinal nerve ligation (SNL); the latter four share mechanisms with CIPN. We included studies with nerve injury models only if their findings were likely to be generalizable to CIPN (i.e., they investigated a mechanism in common with CIPN). Studies on diabetic, herpetic, or other clinically manifesting peripheral neuropathies apart from CIPN were excluded. We only included studies discussing peripheral nervous system mechanisms. These inclusion criteria encompassed 8 studies on CIPN and flavonoids; we selected seven. Similarly, we found 18 studies investigating flavonoids with CCI, SNL, PNL, and SNI, and included four.
3. Flavonoids Counter the Effects of Anticancer Drugs at the Peripheral Nociceptor

3.1. General Effects of Anticancer Drugs and Flavonoids

Oxaliplatin, paclitaxel, and bortezomib destabilize the nociceptor membrane by elevating the resting membrane potential toward the threshold; this increases the likelihood of an action potential. Oxaliplatin activates ion channels involved in action potential initiation and propagation [10,16]. Paclitaxel and bortezomib enhance the release of proinflammatory cytokines, which sensitize peripheral nociceptors [1,2,19] (Figure 3a). Icariin, trimethoxyflavones, and dimethoxyflavones decrease proinflammatory cytokine release and reduce mechanical allosthenia [13–15]. Moreover, quercetin inhibits paclitaxel-induced mast cell degranulation, reducing the release of inflammatory mediators and decreasing the thermal hyperalgesia and mechanical allodynia thresholds [12].

![Diagram of nociceptor sensitization](image_url)

**Figure 3.** Cont.
Figure 3. Effects of anticancer drugs and flavonoids at the peripheral nociceptor. (a) Simplified Overview. Flavonoids counter anticancer drug induced nociceptor sensitization. Anticancer drugs, via the enhanced release of proinflammatory cytokines and activation of ion channels, sensitize the nociceptor, increasing the likelihood that the membrane potential will reach the threshold potential. Thus, there is a greater chance that action potentials will result from weak stimuli that under normal conditions would not reach the threshold potential. (b) Effects of anticancer drugs on the peripheral nociceptor. Anticancer drugs increase the release of proinflammatory mediators such as TNF-α, IL-1β, IL-6, and histamine. These mediators directly sensitize ion channels and activate the ERK/JNK and p38/MAPK pathways, resulting in the activation of Na⁺v. Histamine, prostaglandins, and tryptase bind to their respective receptors and activate the PKA and PKC pathways, which increase the membrane density of TRPV1 and Na⁺v channels. These events ultimately elevate the membrane potential to the threshold value, increasing the likelihood of an action potential; (c) Actions of flavonoids counter anticancer drugs’ effects. Icariin and trimethoxy and dimethoxy flavones decrease the release of TNF-α, IL-1β, IL-6, and IL-8 from astrocytes, microglia, and the DRG, and thereby downregulate the ERK/JNK and p38/MAPK pathways. This reduces the membrane density of ion channels, and consequently decreases the likelihood of reaching the threshold potential and reduces pain signal transmission; (d) Activation of PKA and PKC derivatives by anticancer drugs. Paclitaxel induces the degranulation of mast cells, which release tryptase and other proinflammatory mediators. Tryptase acts on PAR2, leading to PKA activation, the sensitization of TRPV1, TRPA1, and TRPV4, and the increased membrane fusion of Na⁺v. The sensitization of TRP channels increases Na⁺ and Ca²⁺ inflow into the nociceptor. Ca²⁺ causes vesicles to fuse with the membrane and activates PKCδ, CaMKII, and PKCε, which activate TRPV4 and TRPV1, further increasing ion inflow. These events increase the likelihood that the membrane potential will reach the threshold potential; (e) Flavonoids prevent neuropathic pain, affecting PKA and PKC derivatives activation. Quercetin inhibits the translocation of PKCε from the cytoplasm to the membrane and prevents paclitaxel-induced mast cell degranulation. Thus, there is less activation of PKA and PKC derivatives, which leads to decreased channel activation, less ionic influx, and a reduced likelihood that the membrane potential will reach threshold potential; (f) Anticancer drugs lead to the release of...
proinflammatory cytokines, which sensitize the nociceptor. Proinflammatory cytokines act directly on and sensitize TRP channels. They also increase the phosphorylation of transcription factors in the DRG via the p38/MAPK, ERK, and JNK pathways, increasing the synthesis of primary afferent channels; (g) Flavonoids (icariin and trimethoxy and dimethoxy flavones) reduce the release of proinflammatory cytokines by astrocytes, microglia, and the DRG. Thus, they downregulate the p38/MAPK, ERK, and JNK pathways, decrease ion channel density and phosphorylation, and consequently decrease the likelihood that the membrane potential will reach the threshold potential.

3.2. Effects of Anticancer Drugs

3.2.1. Ion Channel Activation

Oxaliplatin upregulates the expression of transient receptor potential melastatin 8 (TRPM8) \[10,16\], causing cold allodynia. It also activates TTX-R Na\(^{+1.8}\) (involved in action potential initiation), TTX-R Na\(^{+1.6}\), and HCN (hyperpolarization-activated channels involved in action potential propagation) while inhibiting TREK1 and TRAAK (potassium channels which restore the membrane potential to the resting state) \[11\]. Furthermore, nerve growth factor (NGF) and ATP activate protein kinase C (PKC) through their actions on TrkA1 and P2X3, respectively; PKC, in turn, increases the membrane fusion of transient receptor potential vanilloid 1 (TRPV1) vesicles \[17,18\]. These increases in ion channel activity and density destabilize the nociceptor membrane and cause the neuron to exhibit oscillatory behavior.

3.2.2. Release of Proinflammatory Mediators

Paclitaxel induces mast cell degranulation \[19\], causing the release of the inflammatory mediators TNF-\(\alpha\), IL-1\(\beta\), IL-6, histamine, prostaglandins, and tryptase \[20\]. Paclitaxel and bortezomib activate macrophages \[1,2\], which release ROS, TNF-\(\alpha\), and IL-1\(\beta\) \[21\]. These mediators act on their respective receptors, inducing a series of events that raise the membrane potential \[22\] (Figure 3b).

ROS directly acts on and sensitizes transient receptor potential ankyrin 1 (TRPA1) \[23\] (Table 1), while TNF-\(\alpha\) and IL-1\(\beta\) act on TNF-R and IL-1R, respectively, leading to extracellular signal-regulated kinase (ERK) activation and p38/MAPK signaling \[17\] (Figure 3d). IL-1\(\beta\) also acts directly on TRPV1, increasing ionic inflow through this channel \[17\]. IL-6 stimulates IL-6R, causing the activation of c-Jun N-terminal kinas (JNK), ERK, and p38/MAPK \[17\]. The IL-6/IL6-R complex subsequently activates PKC\(\delta\), which sensitizes TRPV1 \[24\]. Activation of p38/MAPK leads to phosphorylation of Na\(^{+1.8}\) and Na\(^{+1.9}\) and inhibition of K\(^{+}\)v activity \[8,17,25\]. The recruitment of ERK, JNK, and p38/MAPK pathways result in increased phosphorylation and activation of transcription factors in the DRG; thus, more ion channels are synthesized (long-term changes) \[17\] (Figure 3f). Changes in ion channel density on the nociceptor membrane raise the resting membrane potential toward the threshold, increasing the likelihood that an action potential will result from stimuli too weak to cause one under normal conditions.

Histamine, tryptase, prostaglandins, and bradykinin cause a cascade of events that ultimately increase intracellular IP3 levels \[6,18,20\]. IP3 causes Ca\(^{2+}\) release from intracellular Ca\(^{2+}\)-stores; increased intracellular Ca\(^{2+}\) increases the membrane fusion of vesicles containing substance P and cGRP \[18\]. These neuropeptides act on polymorphonuclear leukocytes, macrophages, and blood vessels, causing them to release increased amounts of proinflammatory mediators in a positive feedback loop \[18\]. Intracellular Ca\(^{2+}\) also activates PKC\(\delta\) and CaMKII, which sensitizes TRPV1 \[18\], and PKC\(\varepsilon\), which sensitizes TRPV4 and TRPV1 \[6\] (Figure 3d). The tryptase/PAR2 complex also leads to PKA activation, which causes the membrane fusion of vesicles containing TTX-R Na\(^{+}\)-channels and sensitizes the TRPV1, TRPA1, and TRPV4 channels \[6,17\]. Furthermore, the histamine/H1R complex leads to the activation of PLA2, which increases the conversion of phospholipid to arachidonic acid. Arachidonic acid is subsequently converted to 12-HPETE, which sensitizes TRPV1 \[26,27\].
Table 1. Mechanisms of CIPN at the peripheral nociceptor induced by anticancer therapy.

| Mechanism of CIPN                                  | Neuropathic Pain Model | Mode of Administration/Concentration (in vitro) | Animal Model | Reference |
|------------------------------------------------------|------------------------|-------------------------------------------------|--------------|-----------|
| Increased macrophage infiltration                   | Paclitaxel and bortezomib induced | IV bortezomib 0.2 mg/kg, 3 times a week for 8 weeks (in vitro) 2 doses of 18 mg/kg paclitaxel given 3 days apart | Female Wistar rats Adult Male Sprague Dawley Rats | [30,31] |
| Sensitization of TRPA1 via increased production of ROS, RNS, and RCS. | Oxaliplatin induced Cisplatin induced Paclitaxel induced | Intraperitoneal/3 mg/kg Intravenous/2 mg/kg Intraperitoneal/3 times per week for 5 weeks (2 mg/kg) Intraperitoneal/6 mg/kg | Male Dunkin-Hartley guinea pigs, male Sprague-Dawley rats, male C57BL/6 mice, wild-type (Trpa1+/+) or TRPA1-deficient mice (Trpa1−/−) Male C57BL/6 mice, wild-type (Trpa1 +/+), or TRPA1-deficient mice (Trpa1 −/−) Male C57BL/6 mice, wild-type (Trpa1 +/+), or TRPA1-deficient mice (Trpa1 −/−) | [32,33] |
| Increased expression of FKN, which binds to CX3CR1, increasing ROS production and enhancing trafficking of macrophages to the sciatic nerve. ROS activated TRPA1, evoking pain. Increased production of tryptase, which cleaves PAR2, causing increases in PKCε and PKA. PKA sensitizes TRPV1, TRPV4 and TRPA1, whereas PKCε sensitizes TRPV1 and TRPV4. IL-1β increases TTXR Na+ currents via the p38/MAPK pathway. | Vincristine induced | Intraperitoneal/0.5 mg/kg for two 5 day cycles | Adult male and female C57BL/6 J mice | [34] |
| Paclitaxel induced                                   | Four doses of 1 mg/kg every two days | | Male ICR mice | [35] |
| Isolated DRG cells                                  | IL-1β (10 ng/mL) applied using multibarrel fast drug delivery system (in vitro) recombinant murine TNF-α (50 µg/mL) solution (in vivo) 1ng of TNFα in 10 µL injected into rat hind paw plantar surface (in vitro) murine TNF-α (0.05–500 ng), murine IL-1β (0.02–200 ng), human IL-8 (0.1 ng to 1 µg), mIL-6 (0.02–200 ng) | Male Sprague-Dawley Rats ICR adult male mice | [36] [37] |
| Application of IL-1β, TNF-α, and IL-6 on peripheral nociceptors dose-dependently led to cGRP release | Incubated skin flaps | | Male Wistar rats | [38] |
| Oxaliplatin induced                                  | (in vitro) Intraperitoneal One dose of 6 mg/kg | | Male Wistar rats | [39] |
| Increased expression of HCN and decreased expression of TREK1 and TRAAK channels. | Oxaliplatin induced | Intraperitoneal 3 injections (1,3,6 mg/kg) | Male C57BL6J mice | [40] |
3.3. Flavonoids Counteract the Effects of Anticancer Drugs

3.3.1. Icariin, Trimethoxy- and Dimethoxyflavones

In paclitaxel-induced models of CIPN, the flavonoid icariin inhibited the release of IL-1β, TNF-α, and IL-6 from the DRG, astrocytes, and microglia [13], while trimethoxy and dimethoxy flavones inhibited the release of IL-1β, TNF-α, and free radicals [14,15] (Table 2). Decreased action of proinflammatory cytokines on the nociceptor would render p38/MAPK, ERK, and JNK less active, decreasing the activation and synthesis of TTX-Resistant Na\(^+\) channels (Figure 3g). Thus, the membrane potential would be less likely to reach the threshold potential (Figure 3c). These factors may account for the reduction of tactile allodynia and thermal hyperalgesia by trimethoxy and dimethoxy flavones and of mechanical allodynia by icariin [13–15].

3.3.2. Quercetin

In a paclitaxel-induced model of CIPN, quercetin inhibited the degranulation of mast cells and thereby reduced histamine release [12]. Decreased histamine-HIR pathway activation reduced HPETE release, IP3 activation, TRPV1 activation, and intracellular Ca\(^{2+}\) release. Quercetin also inhibits PKC epsilon movement from the cytoplasm to the membrane [12]; thus, there is lesser activation of TRPV1 and TRPV4 [6]. Overall, quercetin decreases the intraneuronal concentrations of Ca\(^{2+}\) and Na\(^+\), decreasing the likelihood that the membrane potential will reach the threshold potential. This explains the decrease in thermal hyperalgesia and mechanical allodynia thresholds observed by Gao et al. [12]. Mechanisms of CIPN at the peripheral nociceptor induced by anticancer therapy and the role of flavonoids that counter these effects are summarized in Table 1.
Table 2. Role of flavonoids in countering CIPN mechanisms at the peripheral nociceptor.

| Flavonoid        | Neuropathic Pain Model | Animal Model                                                                                       | Flavonoid Concentration                      | Mechanism-based Intervention                                                                 | Effect on Neuropathy                                                                 | Reference |
|------------------|------------------------|----------------------------------------------------------------------------------------------------|---------------------------------------------|-----------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------|-----------|
| Quercetin        | Paclitaxel induced     | Adult male Sprague-Dawley rats and Institute of Cancer Research mice                                | 3, 10 and 30 μmol/L (in vitro) Intragastric administration of 20 mg/kg or 60 mg/kg once per day for 40 days for rats and 12 days for mice (in vivo) | Inhibited degranulation of mast cells, PKC epsilon translocation from the cytoplasm to the cell membrane | Dose-dependent increase of thermal hyperalgesia and mechanical allodynia thresholds    | [41]      |
| Icariin          | Paclitaxel induced     | 3 to 4 month old male Sprague Dawley Rats                                                         | (in vitro and in vivo) 25, 50, 100 mg/kg     | Reduction of IL-1 β, TNF-α and IL-6 release from the DRG, astrocytes, and microglia              | Decreased mechanical allodynia and spinal neuroinflammation                           | [42]      |
| Trimethoxy flavones | Paclitaxel induced    | Adult swiss Albino mice of either sex                                                                | (in vitro and in vivo) 25, 50, 100 or 200 mg/kg | Concentration-dependent decrease of IL-1β, TNF-α, and free radicals                             | Dose-dependent decrease of tactile allodynia, thermal hyperalgesia, and cold allodynia | [43]      |
| Dimethoxy flavones | Paclitaxel induced    | Male Swiss Albino Mice                                                                               | (in vitro and in vivo) 25, 50, 100 or 200 mg/kg | Concentration-dependent decrease of IL-1β, TNF-α, and free radicals                             | Dose-dependent decrease of tactile allodynia, thermal hyperalgesia and cold allodynia | [44]      |
4. Flavonoids Counter the Effects of Anticancer Drugs at the Dorsal Root Ganglion

4.1. General Effects of Anticancer Drugs and Flavonoids

Anticancer drugs exert various effects on the dorsal root ganglion that eventually lead to receptor sensitization, altered channel expression, inflammation, increased likelihood of an action potential and NT release, and oxidative damage (Figure 4a). Inflammation is mediated by increased proinflammatory cytokine production, mainly through the activation of the transcription factor NF-κB (Figure 4b). Flavonoids interfere with different pathways to decrease chemotherapy-induced inflammation (Figure 4c). Icariin, 7,2′,3′/7,2′,A′/−, 7, 3′, 4′/7,5,4′−trimethoxyflavones and 3′,A′/6,3′/7,2′/7,3′-dimethoxy-flavanol reduce paclitaxel-induced inflammation and allodynia [33–35], whereas 6-methoxyflavone mitigates cisplatin-induced static and dynamic alldynia [38]. Moreover, quercetin and rutin restore the mechanical and cold nociceptive thresholds decreased by oxaliplatin [45].

Figure 4. Cont.
Figure 4. The actions of anticancer drugs (left column) and flavonoids (right column) on a dorsal root ganglion. (a) Simplified Overview. Flavonoids counteract anticancer drugs and increase mitochondrial damage, proinflammatory cytokine production, receptor sensitization, and the likelihood of an action potential. Also depicted is how anticancer drugs increase satellite glial cell coupling and excitability. (b) Anticancer Drugs on Proinflammatory Cytokine Production at the DRG. Anticancer drugs increase the translation of proinflammatory cytokines, prostaglandins, and NO through SIRT1 pathway downregulation and NF-κB activation. This leads to receptor sensitization and an increased likelihood of an action potential firing; (c) Flavonoids on Anticancer Drug-Induced Proinflammatory Cytokine Production in the DRG. Flavonoids counteract anticancer drugs’ actions at the DRG by inhibiting the translocation of NF-κB, upregulating the SIRT1 pathway, and inhibiting the production of proinflammatory cytokines and prostaglandins. These actions decrease inflammation and consequently decrease the likelihood of AP firing and receptor sensitization; (d) Anticancer Drugs on Ion Channels and NT Production at the DRG. Anticancer drugs increase the expression of ion channels such as TRPV1 and N-type VGCC, increasing intracellular Ca$^{2+}$ concentrations and consequently increasing NT release. It also results in a dorsal root reflex; (e) Flavonoids on Anticancer Drug-Induced Increases in NT Production and Ion Channel Expression. 6-MeOF triggers GABAA receptors, decreasing an AP’s likelihood and consequently reducing NT release and alleviating pain; (f) Anticancer Drugs on the DRG’s Oxidative Stress Level. Anticancer drugs increase mitochondrial oxidant production, resulting in lipid peroxidation and tyrosine nitrosylation, lowering GSH levels in the cell and increases oxidative stress, causing neuronal damage; (g) Flavonoids on Anticancer Drug-Induced Increases in DRG Oxidative Stress. Flavonoids counteract the increase in oxidative stress by increasing the translation of GSH and directly scavenging reactive oxygen species; (h) Anticancer Drugs on Satellite Glial Cells. Anticancer drugs increase the expression of gap junctions that connect astrocytes surrounding the same and different DRGs. They also connect SGCs and neurons. Ca$^{2+}$ waves travel through these gap junctions, reducing the membrane potential of SGCs and increasing the likelihood of AP firing in neurons. The Ca$^{2+}$ waves are hypothetically generated by the anticancer drug-induced increase in P2X levels following inflammation. Oxaliplatin blocks the production of Kir4.1, disrupting the extracellular concentration of K$^+$ and leading to an increased likelihood of an AP; (i) Flavonoids on Anticancer Drug Effects in Satellite Glial Cells. No relevant research was found on how flavonoids counteract anticancer drug effects on SGCs. No Specific Effects Known To Date
4.2. Effects of Anticancer Drugs

4.2.1. Upregulation of the NF-κB Pathway

Paclitaxel activates NF-κB by stimulating TLR4 and upregulating ERK/JNK signaling [46]. These events lead to the phosphorylation and nuclear translocation of NF-κB, increasing the acetylation of the histone H4 and resulting in the transcription of various proinflammatory factors such as CX3CL1, TNF-α, IL-1β, and IL-6 [46] (Figure 4d). Oxaliplatin stimulates NF-κB through the JAK/STAT pathway and causes the production of proinflammatory factors such as CXCL12. Furthermore, this leads to increased MC-P1 (CCL2) transcription in the DRG and its receptor (CCL2R) on macrophages. Activation of CCL2R induces proinflammatory cytokine release, increasing the innate immune response [47]. Cisplatin also uses NF-κB to mediate its proinflammatory effects through the production of nitric oxide and prostaglandins. These factors contribute to inflammation, which leads to membrane depolarization and an increased chance of an AP firing [48].

4.2.2. Increase in Intracellular Ca$^{2+}$

Cisplatin increases N-type voltage-gated Ca$^{2+}$ channel (VGCC) density in small DRG neurons [49] by activating CaMKII [50]. Paclitaxel and oxaliplatin upregulate the α2δ1 subunit [51,52] (Table 3), which increases VGCC currents, prolongs the neuronal response to mechanical and thermal stimuli, and increases pain [50]. Elevated VGCC mRNA and protein expression [50] increase VGCC density at the presynaptic membrane; therefore, more Ca$^{2+}$ enters the presynaptic terminal. Prostaglandins and bradykinin act on G, upregulating IP3 and increasing intracellular Ca$^{2+}$ release [53]. ATP acts on P2X purinoceptor 3 (P2X3), leading to an increase in intracellular Ca$^{2+}$ [53]. Ca$^{2+}$ activates CaMKII and PKC epsilon, which phosphorylate and activate TRPV1 [53]. Ca$^{2+}$ also increases the fusion of vesicles containing substance P, cGRP, and glutamate with the presynaptic membrane [53] (Figure 4e). The result is an increased probability of postsynaptic action potential generation and a consequent increase in neuropathic pain severity.

4.2.3. Increased GABA Release

The release of more NT by the mechanisms described above increases interneuron activation and GABA release. GABA acts on GABAA receptors on DRG neurons, causing an efflux of Cl$^{-}$ that contributes to the dorsal root reflex, by which the axonal membrane is depolarized in the reverse direction [54]. The reverse ion flow enhances the depolarization of the nociceptor membrane, causing increased release of substance P and cGRP and the consequent release of proinflammatory mediators in a positive feedback loop (see Section 3). In a cisplatin-induced neuropathic pain model, the flavonoid 6-methoxy-flavone increased Cl$^{-}$ influx through GABAA channels [18] and thus decreased presynaptic membrane depolarization and the dorsal root reflex. Smaller amounts of NT were released, decreasing the frequency of action potentials in the postsynaptic neuron and alleviating static and dynamic allodynia [18].

4.2.4. Enhanced Activation of Satellite Glial Cells

Oxaliplatin and taxol contribute to CIPN by activating and increasing satellite glial cells’ coupling (SGC). SGC coupling and increases in GFAP due to ROS production are hypothesized to activate SGCs. Oxaliplatin induces the release of the pro-inflammatory cytokines IL-6 and TNF-α, promoting neuronal hyperexcitability and upregulating the purinergic receptor P2X, increasing the sensitivity to ATP, whose concentration is elevated due to increased action potential firing. Moreover, P2X upregulation increases intra-SGC Ca$^{2+}$ flow and causes intracellular Ca$^{2+}$ waves (ICW) that travel through gap junctions between SGCs and neurons. ICW transmission between SGCs surrounding different neurons causes both SGC and neuronal hyperexcitability [55].
Table 3. Previous studies investigating the mechanisms by which anticancer drugs exert their effects on the DRG.

| Mechanism of CIPNP | Neurpathic Pain Model | Mode of Administration/Concentration | Animal | Reference |
|--------------------|------------------------|--------------------------------------|--------|-----------|
| Increased VGCC current density in DRG neurons via CaMKII; Increased VGCC protein levels | Cisplatin induced | 5 mg/kg (in vivo), 0.5 µM and 5 µM (in vitro) | Male and female Wistar rats for in vitro procedures. Male Sprague-Dawley rats for in vivo procedures | [49] |
| Upregulation of VGCC α2δ1 subunit in DRG | Paclitaxel induced | IP/4 mg/kg single injection; 4 mg/kg administered 4 times on alternate days Intravenous/ 4 mg/kg single injection | Male ddY mice | [57] |
| Increased phosphorylation of STAT3; increased levels of CXCL12 mRNA and protein | Oxaliplatin induced | IP/5 injections of 4 mg/kg each, administered on consecutive days Intraperitoneal/ | Male Sprague–Dawley rats | [58] |
| Increased lipid peroxidation and protein nitrosylation; increased inducible nitric oxide synthase. Activation of astrocytes | Oxaliplatin induced | 5 injections of 4 mg/kg each, administered on consecutive days | Male Sprague-Dawley rats | [59] |
| Downregulation of SIRT1 expression and an increase in histone acetylation; induction of NF-kB (p65) activation and nuclear translocation; upregulation of proinflammatory factors (TNF-α, IL-1β, IL-6); | Paclitaxel induced | IP/8 mg/kg per day for 3 consecutive days | Male Sprague Dawley rats | [42,43] |
| Stimulates COX-2 expression | Oxaliplatin induced | IV/1 mg/kg dose twice a week (total of nine injections). | Male Swiss mice | [56] |
| TLR4 signaling in the spinal cord dorsal horn and DRG induces and maintains CIPN | Paclitaxel induced | IP/A single dose (10 mg/kg) | Male Swiss albino mice | [44] |
| Upregulation of CX3CL1 via NF-κB-dependent H4 acetylation | Paclitaxel induced | IP/4 injections of 2 mg/kg administered every other day | Male Sprague-Dawley rats | [48] |
| Increased VGCC expression mediated by CaMKII | Oxaliplatin induced | IP/3 injections of 8 mg/kg, on 3 alternate days | Male Sprague-Dawley rats | [47] |
| Increased gap-junctional coupling among SGCs; increased GFAP production increased ROS, GFAp, and Cx-43 decreased Kir4.1 channels | Taxol and Oxaliplatin induced | Oxaliplatin-IP/ 2 injections of 4 mg/kg-3 days apart. Taxol- IP/ 2 injections of 18 mg/kg-3 days apart in vitro/ 1 and 10 µM for 24 and 24 h. | Male Wistar rats | [39] |
| Peripheral neuropathic pain associated with increase in α2δ1 subunit in spinal cord | Oxaliplatin induced | In vitro/Intraperitoneal 2 mg/kg paclitaxel on 4 alternate days In vitro/ 6 mg/kg oxaliplatin intraperitoneal | Male Sprague Dawley Rats | [51,52] |
| Increased N-type VGCC density in small DRG neurons | Oxaliplatin induced | In vitro/0.5 μM and 5 μM incubated for 24 or 48 h. | Male and female Wistar rats | [49] |
Increased SGC coupling is explained by the oxaliplatin-induced upregulation of Cx-43, a crucial connexon between SGCs. Oxaliplatin also downregulates the inward rectifier channel K\textsubscript{ir} 4.1, reducing the resting membrane potential and disrupting extracellular K\textsuperscript{+} concentrations. Both of these effects cause the depolarization of SGC-surrounded neurons and thus increase the likelihood of action potential firing (Figure 4h).

4.2.5. Increased Oxidative Stress

Oxaliplatin increases the production of nitric oxide and superoxide, which react to form peroxynitrite. Peroxynitrite is highly reactive and gives rise to nitrogen dioxide and hydroxyl radicals that interact directly with lipids and tyrosine, leading to lipid peroxidation and protein nitrosylation in the DRG ultimately neuronal damage and death through ROS elevation and GSH depletion. Cisplatin accumulation also causes lipid peroxidation and increases inducible nitric oxide synthase (iNOS) activity, and thereby induces oxidative stress and neurotoxicity (Figure 4f). Similarly, paclitaxel induces oxidative stress by increasing DPPH and nitric oxide levels in the DRG [48]. In contrast, thalidomide may cause axonal sensory neuropathy through the depletion of nerve growth factor (NGF). NGF regulates neuronal growth, maintenance, and survival; its depletion is associated with peripheral neuropathy [45].

4.3. Flavonoids Counteract the Effects of Anticancer Drugs

4.3.1. Icariin

Icariin activates the sirtuin 1 (SIRT1) pathway, which counteracts paclitaxel-induced NF-κB acetylation of H4 [33]. SIRT1 is a histone deacetylase that may be activated in a NAD-dependent or independent manner. It deacetylates LKB-1, which then activates AMPK. AMPK activates nicotinamide phosphoribosyl-transferase and thus increases NAD+, which is needed for SIRT1 activation [39]. Icariin also directly inhibits NF-κB phosphorylation and nuclear translocation. In contrast, 6-methoxyflavone decreases cisplatin-induced inflammation by inhibiting the enzyme cyclooxygenase 2 (COX-2) [15].

4.3.2. Quercetin, Rutin, and Trimethoxy and Dimethoxy Flavones

Flavonoids alleviate anticancer drug effects by decreasing oxidative stress in the DRG. Quercetin and rutin counteract oxaliplatin’s effects by directly increasing GSH levels and scavenging ROS [56]. Quercetin also decreases the levels of catalase and superoxide dismutase (SOD) and consequently decreases lipid peroxidation and protein oxidation. 7,2′,3′/7,2′/4′/−,7,3′,4′/7,5,4′–trimethoxyflavones and 3′,4′/6,3′/7,2′/7,3′-dimethoxyflavanol also counteract paclitaxel-induced neurotoxicity by scavenging DPPH and nitric oxide [43] (Figure 4g) (Table 4). These flavonoids also inhibit the production of TNF–α and IL-1β [34].

No research on the potential effects of flavonoids on SGCs was found (Figure 4i); thus, future studies should investigate this.
| Flavonoid                  | Neuropathic Pain Model | Animal                        | Mode of Administration/ Concentration of Flavonoid | Mechanism-Based Intervention                                                                 | Effect on Neuropathy                                                                 | Reference |
|---------------------------|------------------------|-------------------------------|----------------------------------------------------|---------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------|-----------|
| Icariin                   | Paclitaxel induced     | Male Sprague Dawley rats     | IG/25, 50, 100 mg/kg.                              | Activated SIRT1 via histone acetylation; Prevented NF-κB(p65) phosphorylation and nuclear translocation; prevented the production of TNF-α, IL-6, and IL-1β; Suppressed astrocyte activation. | Alleviated mechanical allodynia. (100 mg/kg in the long term) and spinal neuroinflammation. | [42]      |
| Rutin and quercetin       | Oxaliplatin            | Male Swiss mice              | IP/ rutin or quercetin (25, 50, and 100 mg/kg) 30 min before every oxaliplatin injection (1 mg/kg). | Decreased Fos expression; Decreased nitrotyrosine and iNos expression, and lipid peroxidation. | Inhibited the decrease in mechanical (a.d) and cold nociceptive threshold. Prevented the shrinkage of dorsal horn neurons. | [56]      |
| 7, 2', 3'/7,2', 4'/−,7,3',4'/7, 5,4'-trimethoxy flavone | Paclitaxel              | Male and female adult Swiss albino mice | SC injection/ 25, 50, 100 and 200 mg/kg. | Inhibition of TNF–α, IL–1β (d.d). Scavenging DPPH; Preventing NO generation (d.d) | Alleviated tactile allodynia, cold alldynia and thermal hyperalgesia in mice | [43]      |
| 3',4'/6,3'/7,2'/7,3'-dimethoxy flavonol | Paclitaxel              | Male Swiss albino mice       | SC/25, 50, 100, and 200 mg/kg | Decreased TNF-α, IL-1β (d.d); Scavenged DPPH and NO (d.d) | Improved tactile allodynia, cold alldynia and thermal hyperalgesia(d.d) | [44]      |
| 6-Methoxyflavone          | Cisplatin              | Male Sprague-Dawley rats     | Intraperitoneal/25, 50 and 75 mg/kg Also conducted in silico and in vitro studies | Inhibits COX-2; Stimulates GABAA channels | Improved static and dynamic allodynia | [48]      |
5. Flavonoids Counter the Effects of Anticancer Drugs at the Spinal Cord Dorsal Horn

5.1. General Effects of Anticancer Drugs and Flavonoids

Cisplatin and carboplatin increase proinflammatory cytokine release by astrocytes and microglial cells [7,64], contributing to peripheral sensitization. Oxaliplatin similarly enhances cytokine release and peripheral sensitization by increasing astrocyte coupling [65]. Paclitaxel and bortezomib increase synaptic glutamate concentrations [66,67], increasing the likelihood of action potential generation in the postsynaptic neuron (Figure 5a). Increased postsynaptic action potential frequency intensifies neuropathic pain. Quercetin reverses the paclitaxel-induced decrease in thermal hyperalgesia and mechanical allodynia thresholds [41], while icariin alleviates paclitaxel-induced mechanical allodynia and spinal neuroinflammation [42].

5.2. Effects of Anticancer Drugs

Cisplatin and carboplatin are ligands for TLR4 [7,64], and cisplatin upregulates the TREM-2 ligand [68] (Table 5). Subsequent activation of the TLR4 and TREM-2 pathways eventually results in NF-κB activation, culminating in proinflammatory cytokine release by astrocytes and microglial cells [69]. Chemokines released by DRG neurons, such as CX3CL1, also cause NF-κB activation and proinflammatory cytokine release [7,70] (Figure 5b). Proinflammatory cytokines cause peripheral sensitization via the processes mentioned in Section 2; IL-1β acts on IL-1R on astrocytes, stimulating NF-κB activation and hence the release of more proinflammatory cytokines [71]. These cytokines also stimulate the fusion of presynaptic glutamate vesicles with the DRG neuron membrane [67].

Table 5. Studies investigating the mechanisms by which anticancer drugs exert their effects.

| Mechanism of CIPN                                                                 | Neutrophic Pain Model | Mode of Administration/Concentration                                                                 | Animal                              | Reference |
|----------------------------------------------------------------------------------|-----------------------|--------------------------------------------------------------------------------------------------------|-------------------------------------|-----------|
| Strong TREM2/DAP12 signaling continuously activated microglial cells,             | Cisplatin induced     | Intraperitoneal/Accumulated dose of 23 mg/kg delivered in 2 rounds daily for 5 days with a 5 day break between rounds. (in vitro and in vivo) | Adult male mice, 9–10 weeks old    | [68]      |
| which resulted in neuropathic pain.                                               |                       |                                                                                                       |                                     |           |
| Oxaliplatin upregulates spinal CX3CL1, causing central sensitization and acute CIPN | Oxaliplatin induced   | Intraperitoneal/single dose of 4 mg/kg (in vitro and in vivo)                                        | Male Sprague Dawley rats            | [70]      |
| Increased S1P, S1PR1, and dihydro-S1P due to dysregulated sphingolipid metabolism| Bortezomib induced    | (in vitro and in vivo)                                                                                | Male Sprague Dawley rats, S1pr1 knockout and knockdown mice | [67]      |
| Downregulation of GLAST and GLT-1 on astrocyte membranes                         | Paclitaxel induced    | Intraperitoneal/4 injections of 2 mg/kg every other day (in vitro)                                    | Adult male Sprague Dawley Rats, 8–10 weeks old | [66]      |
| Upregulation of CX43 gap junctional proteins in astrocytes in the spinal cord dorsal horn | Oxaliplatin induced   | Intraperitoneal/4 injections of 2 mg/kg each given every other day. (in vitro and in vivo)             | Male Sprague Dawley rats            | [65]      |
Figure 5. Anticancer drugs modulate signal transmission at a synapse in the dorsal horn spinal cord, and flavonoids counter these effects; (a) Simplified Overview of how flavonoids counter the effects of anticancer drugs at the spinal cord dorsal horn. (b) Actions of anticancer drugs at the spinal cord dorsal horn. Anticancer drugs increase presynaptic NT release and the likelihood of postsynaptic neuronal activation and activate microglial cells and astrocytes, releasing proinflammatory cytokines. Proinflammatory cytokines increase glutamate release and sensitize primary afferent channels; (c) Flavonoids counteract anticancer drugs’ actions at the dorsal horn by inhibiting mast cell degranulation, PKC epsilon translocation, and NF-κB activation. This decreases the likelihood of postsynaptic action potential generation; (d) Anticancer drugs increase intracellular Ca\(^{2+}\) at the synaptic terminal in DRG neurons via activation of VGCC and histamine release, which leads to TRPV1 sensitization; (e) Flavonoids reduce neuropathic pain by inhibiting mast cell degranulation. Thus, histamine release and H1R activation decrease, eventually leading to decreased NT release.
Paclitaxel inhibits GLAST and GLT-1 (glutamate uptake channels) located on astrocyte membranes [66]. Bortezomib increases sphingolipid metabolism, resulting in increased synthesis of S1P receptors [67]. Alternatively, S1P is upregulated by increases in peripheral TNF-α, IL-1β, and IL-6, commonly seen in neuropathic pain states. Increased S1P is correlated with increased presynaptic membrane fusion of glutamate vesicles [67]. These changes increase synaptic glutamate levels, upregulating NMDA and AMPA on the postsynaptic membrane. They contribute to neuropathic pain by increasing the postsynaptic neuron’s depolarization and consequently increasing the chance of generating an action potential.

Oxaliplatin upregulates the CX43 gap junctional protein, increasing coupling between astrocytes [65]. This increases astrocyte activation and proinflammatory cytokine release. Furthermore, histamine released by mast cells acts on H1R; the subsequent cascade results in arachidonic acid production. Arachidonic acid activates 12 HPETE, which in turn sensitizes TRPV1 (Figure 5d) [41]. More Ca^{2+} enters the presynaptic neuron, causing more vesicle fusion and NT release, thereby increasing the likelihood of generating a postsynaptic action potential, increasing neuropathic pain intensity.

5.3. Flavonoids Counter the Effects of Anticancer Drugs

Quercetin and Icariin

The flavonoid quercetin inhibits mast cell degranulation and PKC epsilon movement to the membrane, thus decreasing the activation of TRPV1 (Figure 5e) [41]. This reduces Ca^{2+} entry and thus the fusion of vesicles with the membrane, decreasing the likelihood of a postsynaptic action potential. Icariin inhibits NF-κB in the spinal cord dorsal horn (Figure 5e) (Table 6); thus, fewer proinflammatory cytokines are released, reducing the fusion of vesicles with the membrane. Overall, the frequency of action potentials in the postsynaptic neuron decreases, decreasing neuropathy intensity [42] (Figure 5c).

| Flavonoid | Neuropathic Pain Model | Animal | Mode of Administration/ Concentration of Flavonoid | Mechanism-based Intervention | Effect on Neuropathy | Reference |
|-----------|------------------------|--------|-----------------------------------------------|-------------------------------|----------------------|----------|
| Quercetin | Paclitaxel induced      | adult male Sprague-Dawley rats and mice | 3, 10 and 30 µmol/L (in vitro) Intragastral administration of 20 mg/kg or 60 mg/kg per day for 40 days for rats and 12 days for mice (in vivo) | Inhibited degranulation of mast cells and membrane translocation of PKC epsilon | Dose dependent increase of thermal hyperalgesia and mechanical allodynia thresholds Alleviated mechanical allodynia (100 mg/kg in the long term) and spinal neuroinflammation. | [41]     |
| Icariin   | Paclitaxel induced      | Male Sprague Dawley rats | IG/25, 50, 100 mg/kg. | Suppressed GFAP and astrocyte production of TNF-α, IL-1β, and IL-6. | | [42]     |

6. Flavonoids Counter the Effects of Anticancer Drugs on Astrocytes and Microglial Cells at the Spinal Cord Dorsal Horn

6.1. General Effects of Anticancer Drugs and Flavonoids

Bortezomib causes astrocyte activation and glutamate release by upregulating the S1P pathway; this leads to peripheral sensitization and an increased likelihood of postsynaptic action potential generation [67]. Cisplatin upregulates TREM2/DAP12 and TLR4 signaling [57,64,69], causing proinflammatory cytokine release and thus peripheral sensitization. Vincristine exerts the same effects by upregulating Iba-1, CX3CR1, and p-p38 [72]. Oxaliplatin and paclitaxel enhance astrocyte activation, increasing the likelihood of postsynaptic action potential generation [63] (Figure 6a). Astragli radix decreases astrocyte and microglial activation and oxaliplatin-induced neuronal damage, while icariin reduces proinflammatory cytokine release and astrocyte activation [42,73].
Figure 6. The actions of anticancer drugs (left) and flavonoids (right) on astrocytes and glial cells. (a) Simplified Overview of how flavonoids counteract the mechanisms of anticancer drugs at the level of astrocytes and microglial cells. (b) Anticancer Drugs on Astrocytes. Anticancer drugs activate NF-κB and consequently lead to the production of proinflammatory cytokines that sensitize neuronal receptors. Bortezomib increases the levels of S1P, which is hypothesized to increase presynaptic NT release. Paclitaxel blocks glutamate receptors, thus increasing its extracellular concentration and increasing the likelihood of an AP in the post-synaptic neuron. (c) Flavonoids on Anticancer Drug-Induced Increases in Proinflammatory Cytokines in Astrocytes. Icariin inhibits NF-κB and thus counteracts the increase in proinflammatory cytokine levels, decreasing neuronal sensitization and inflammation. (d) Anticancer Drugs on Glial Cells. Anticancer drugs activate NF-κB and CREB, leading to proinflammatory cytokines and NO production, ultimately causing neuronal receptor sensitization. (e) No specific effects of flavonoids on microglial cells are elucidated to-date. Studies usually investigate the spinal cord dorsal horn as a whole.
6.2. Effects of Anticancer Drugs

6.2.1. Upregulation of the S1P Pathway

Bioactive sphingolipid metabolites are potent signaling molecules involved in bortezomib-induced CIPN. Bortezomib affects the S1P signaling pathway by increasing ceramide and its biosynthetic precursors such as S1P (Figure 6b). As astrocytes express S1PR1 (at higher levels than glial cells), they mediate bortezomib-induced CIPN; S1P triggers them to become reactive (Table 7). This form of astrocyte activation is associated with increases in GFAP, TNF, and IL-1β. S1PR1-induced inflammation establishes a feed-forward mechanism that dysregulates sphingolipid production, as TNF and IL-1β cause the activation of enzymes in the ceramide and S1P pathways. S1PR1 also increases glutamate release, which sustains neuropathic pain [67].

Table 7. Previous studies investigating the mechanisms by which anticancer drugs exert their effects.

| Mechanism of CIPNP | Neurogenic Pain Model | Mode of Administration/Concentration | Animal | Reference |
|--------------------|-----------------------|---------------------------------------|--------|-----------|
| Increased sphingosine metabolism and consequently increased ceramide, DH-S1P, and S1P. Increased TNF-α and IL-1β in blood plasma | Bortezomib induced | Intraperitoneal/total 1 mg/kg over 5 consecutive days (0.2 mg/kg per day) and Intraperitoneal/0.4 mg/kg every other day 3 times a week for 4 weeks Intraperitoneal/ | Male Sprague Dawley rats and GFAP-Cre breeder mice | [67] |
| Upregulated TREM2 ligand and thus increased TREM2/DAPI2 complex signaling, leading to the activation of microglial cells | Cisplatin induced | Intraperitoneal/23 mg/kg spread over 2 rounds of 5 consecutive days with a 5day break Intraperitoneal/1 mg/kg per day for 2 weeks Intraperitoneal/2 mg/kg every alternate day | Adult male mice | [68] |
| Increase in the astrocyte-specific gap junctional protein CX43 in the spinal cord, leading to enhanced astrocyte activation. | Oxaliplatin induced | Intraperitoneal/4 injections of 2 mg/kg each, every other day Intraperitoneal/4 injections of 1 mg/kg per day for 4 consecutive days Intraperitoneal/1.0 mg/kg on 4 alternate days, total 4 mg/kgIntraperitoneal/2 mg/kg every other day for total 4 injections | male Sprague-Dawley rats | [65] |
| Downregulation of GLAST and GLT-1 in the spinal cord dorsal horn led to excessive activation of postsynaptic AMPA and NMDA receptors | Paclitaxel induced | Intraperitoneal/1 mg/kg per day for 4 consecutive days Intraperitoneal/1.0 mg/kg on 4 alternate days, total 4 mg/kgIntraperitoneal/2 mg/kg every other day for total 4 injections Intraperitoneal/6 injections of 2.3 mg/kg given every other day | male Sprague–Dawley ratsadult male Sprague–Dawley rats Adult male Sprague-Dawley rats Wild type C57BL/6 mice; Tlr3–/–, Tlr4–/–, and Myd88–/– mice | [66,74,75] |
| TLR4, through MYD88 and TRIF, plays an integral role in nociceptive signaling. | Cisplatin induced | Intraperitoneal/ | | [64] |
| TLR4 signaling in the spinal cord dorsal horn and DRG induces and maintains CIPN | Paclitaxel induced | Intraperitoneal/4 injections of 2 mg/kg administered every other day | Male Sprague–Dawley rats | [60] |

6.2.2. Upregulation of the TLR4 Pathway

Cisplatin activates TLR4 receptors via the MYD88/NF-κB pathway, leading to the release of inflammatory cytokines like TNF and consequent mechanical allodynia. Activating transcription factor 3 (ATF3), whose concentration increases during inflammation, augments TLR4 signaling to NF-κB. This pathway is also seen in microglia [64].

Similarly, paclitaxel exerts its effects through TLR4 signaling—a pathway shared by IL-1 receptors, which are activated by proinflammatory cytokines elevated by paclitaxel as shown (see Figure 6b). Both TLR4 and IL-1 receptors can activate MyD88 dependent cascades, leading to early NF-κB activation. MyD88 is an adaptor protein that links to the IL-1 receptor-associated kinase (IRAK); TNF receptor-associated factor 6 (TRAF6) lies downstream. When TRAF6 is activated, it becomes ubiquitinated and interacts with TAB1, TAB2, and the kinase TAK1, activating another kinase, IKK-2. IKK-2 then phosphorylates IκB, causing NF-κB phosphorylation and nuclear translocation [42,57].

6.2.3. Increased Expression of Cx-43

Besides upregulating GFAP (as with paclitaxel), oxaliplatin upregulates Cx-43, a component of the gap junctions between astrocytes. Cx-43 mediates the exchange of ions, metabolites, glia-transmitters, and the propagation of Ca2+ waves between astrocytes. It increases astrocyte coupling and activation and consequently plays a role in oxaliplatin-induced hypersensitivity [63].
6.2.4. Downregulation of Glutamate Uptake Receptors and Increased GFAP

Paclitaxel activates astrocytes and not microglial cells. As glutamate is a major excitatory NT, regulation of its uptake is essential. Paclitaxel downregulates the glial glutamate receptors GLAST and GLT-1 on astrocytes. Consequently, paclitaxel induces nociceptive behaviors and hypersensitivity to peripheral thermal and mechanical stimuli due to glutamate’s impaired clearance in the inter-synaptic space [56]. Paclitaxel also increases the expression of GFAP, further supporting the astrocyte activation hypothesis in parallel with hypersensitivity [42].

6.2.5. Enhanced TREM2/DAP12 Signalling

Cisplatin enhances the triggering receptor’s expression on myeloid cells 2 (TREM2) /DNAX-activating protein of 12 kDa (DAP12) signaling in spinal microglia. TREM2, from the immunoglobulin/lectin superfamily, associates with DAP12 to mediate intracellular interaction through the phosphorylation of tyrosine residues in its immunoreceptor tyrosine activation motif (ITAM) motifs. ITAM later activates phosphatidylinositol 3 kinase (PI3K) and downstream effectors until NF-κB is active, increasing proinflammatory cytokines such as IL-1β, IL-6, and TNF-α, iNOS, and CD16 [69].

6.2.6. Increased CX3CL1 Expression

CX3CL1 is a chemokine that stimulates spinal microglia by acting in its G-protein coupled receptor CX3CL1R to release pain mediators. Vincristine upregulates Iba-1, CX3CR1, and p-p38, which eventually activate NF-κB and CREB. NF-κB and CREB activate the microglia, which release proinflammatory cytokines (TNF-α and IL-1β) (Figure 6d). Soluble CX3CL1 activates the microglia-specific receptor CX3CR1, causing the phosphorylation of p38 MAPK, thereby promoting proinflammatory cytokines’ secretion. Targeting of the Notch signaling pathway inhibits this CX3CL1/p38 signaling pathway through a mechanism not entirely elucidated [72]. No specific effects of flavonoids on spinal microglial cells are known to date (Figure 6e); thus, this is an area of investigation of future research.

6.3. The Flavonoids Icariin and Astragali Radix Counter the Effects of Anticancer Drugs

Icariin counteracts paclitaxel-induced GFAP expression and thus represses astrocyte activation. Icariin also inhibits the production of proinflammatory cytokines such as TNF-α, IL-1β, and IL-6 in the spinal cord [42] (Table 8) (Figure 6c). In addition to isolated flavonoids, Astragali radix is an adaptogenic herbal product that improves chemotherapy patients’ quality of life. Astragai radix is rich in various phytochemicals, including isoflavonoids, while isoflavones are more concentrated in hydroalcoholic extracts of Astragali radix when compared with aqueous. Besides, 50% hydroalcoholic extracts of Astragali radix reduced ATF-3 nuclear immunoreactivity in L4-L5 DRG, oxaliplatin-induced molecular and morphometric alterations in peripheral nerve and dorsal root ganglia, and the activation of microglia and astrocytes in a Sprague-Dawley rat model of oxaliplatin-induced neurotoxicity [73].
Table 8. Previous studies investigating the effects of flavonoids on CIPN models.

| Flavonoid      | Neuropathic Pain Model                | Animal                        | Mode of Administration/Concentration of Flavonoid | Mechanism-based Intervention                                                                 | Effect on Neuropathy                                                                                     | Reference |
|----------------|---------------------------------------|-------------------------------|---------------------------------------------------|------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------|-----------|
| Icariin        | Paclitaxel induced                    | Male Sprague Dawley rats      | IG/25, 50, 100 mg/kg                              | Suppressed GFAP and astrocyte production of TNF-α, IL-1β, and IL-6.                                 | Alleviated mechanical alldynia (100 mg/kg in the long term) and spinal neuroinflammation.               | [42]      |
| Astragali radix| Oxaliplatin-induced neurotoxicity     | Male Sprague Dawley rats      | 50% hydroalcoholic extracts of Astragali radix     | Numerical reduction of astrocytes within the dorsal horns (demonstrated by GFAP immunohistochemistry) | Reduction of Oxaliplatin-induced molecular and morphometric alterations in peripheral nerve and dorsal-root ganglia. Decrease in the activation of microglia and astrocytes | [73]      |
7. Flavonoids Counter Neuronal Injury Induced by Anticancer Drugs

7.1. General Effects of Anticancer Drugs and Flavonoids

Anticancer drugs cause mitochondrial and neuronal damage [76,77] and upregulate iNOS [56]. Flavonoids restore ATP levels and mitochondrial protective enzymes, reverse neuronal damage, and decrease ROS production [78–81] (Figure 7a). Thus, they reduce spontaneous pain, ongoing pain, and mechanical hypersensitivity.

Figure 7. Anticancer drugs cause neuronal injury, and flavonoids counter these effects; (a) Simplified Overview of how flavonoids counter neuronal injury induced by anticancer drugs (b) Mechanisms of neuronal injury by anticancer drugs. Mitochondrial damage and sensitization of primary afferent channels cause ectopic discharges, which contribute to spontaneous pain, ongoing pain, and mechanical hypersensitivity; (c) Flavonoids alleviate neuronal damage caused by anticancer drugs, reducing spontaneous pain, mechanical hypersensitivity, and the likelihood of apoptosis.
7.2. Effects of Anticancer Drugs

7.2.1. Mitochondrial Damage

Paclitaxel increases the activity of the mitochondrial permeability transition pore (mPTP) channel [76] (Table 9). Consequently, more Ca\(^{2+}\), caspases, and calpains leave the mitochondria; caspases and calpains trigger neuronal apoptosis [77]. Furthermore, paclitaxel, vincristine, and bortezomib disrupt microtubules (Figure 7b) [82,83]. Paclitaxel causes microtubules to polymerize and inhibits their depolymerization [84]. Platinum compounds cause DNA adducts to form within mitochondria and the neuronal nuclei [85]. Nuclear DNA adducts activate PARP, decreasing mitochondrial NAD\(^{+}\) and ATP and causing further mitochondrial damage [86]. Under these low ATP conditions, intraepidermal nerve fibers are lost [87].

7.2.2. Neuronal Damage

Furthermore, the activity of the Na\(^{+}/K\(^{+}\) exchange will decrease, leading to increased ectopic activity [88]. Ectopic activity leads to spontaneous pain, ongoing pain, and mechanical hypersensitivity [76]. Mitochondrial DNA adducts damage the electron transport chain’s proteins, increasing oxidative stress and H\(_2\)O\(_2\) release [76]. H\(_2\)O\(_2\) causes ROS formation and demyelinates the neuron; ROS causes p. 53 and Bax release, leading to neuronal apoptosis [77]. ROS also increases the release of proinflammatory cytokines, which cause peripheral sensitization, further contributing to ectopic activity [89]. Damage to electron transport chain proteins causes the downregulation of protective enzymes such as SOD, GAPDH, GSH, and GPX, leading to excessive ROS production [76].

7.2.3. Enhanced iNOS Expression

Oxaliplatin increases LPS-induced iNOS expression [56]. Ca\(^{2+}\), together with iNOS, leads to the production of NOS, which increases NO. NO combines with oxygen free radicals to form ONO\(_2\)\(^{-}\), enhancing DNA adducts production [56].

7.3. Flavonoids Counter the Effects of Anticancer Drugs

The flavonoids morin and GSPE restore GSH levels, and morin restores ATP levels (Figure 7c) [78,79]. Increased ATP levels restore the activity of the Na\(^{+}/K\(^{+}\) exchanger, decreasing ectopic activity and thus neuropathic pain, while elevated GSH levels reduce H\(_2\)O\(_2\) and ROS production. These effects reduce the chance of apoptosis and also decrease ectopic activity. Thus, spontaneous pain, ongoing pain, and mechanical hypersensitivity will all decrease. Genistein restores mitochondrial GPX levels while isoorientin ameliorates axonal swelling and prevents demyelination [80,81]. Quercetin, rutin, and genistein reduce LPS-induced iNOS expression [56,81] and thereby reduce ONO\(_2\)\(^{-}\) production and DNA adduct formation. Besides, the natural flavonoid silibinin prevents oxidative damage and exerts antineuropathic effects in a rat model of painful oxaliplatin-induced neuropathy [90] (Table 10).
Table 9. Previous studies investigating the mechanisms by which anticancer drugs exert their effects.

| Mechanism of CIPNP | Neuropathic Pain Model | Mode of Administration/Concentration | Animal | Reference |
|--------------------|------------------------|--------------------------------------|--------|-----------|
| Downregulation of MnSOD through post translational nitration by peroxynitrite. | Paclitaxel, oxaliplatin, bortezomib | Intraperitoneal; Paclitaxel: 4 doses delivered on alternate days, cumulative dose of 8 mg/kg; Oxaliplatin: 10 mg/kg delivered over 5 consecutive days; Bortezomib: 1 mg/kg delivered over 5 consecutive days | Male Sprague Dawley rats | [91] |
| Formation of DNA adducts | Cisplatin | Intraperitoneal; 2 microgram/ml for 48 h (in vitro) | Harlan–Sprague–Dawley rats and wild type background mice (C57BL/6J) | [85] |
| Increased permeability of mPTP | Paclitaxel | Intraperitoneal/ 1 ml/kg on 4 alternate days (in vitro and in vivo) | Adult male Sprague-Dawley rats | [92] |
| Increased LPS-induced iNOS expression | Oxaliplatin | i.v./nine injections of 1 mg/kg each given twice a week (in vitro and in vivo) | male Swiss mice | [56] |

Table 10. Previous studies investigating the effects of flavonoids on CIPN models.

| Flavonoid | Neuropathic Pain Model | Animal | Mode of Administration/Concentration of Flavonoid | Mechanism Based Intervention | Effect on Neuropathy | Reference |
|-----------|------------------------|--------|--------------------------------------------------|------------------------------|----------------------|-----------|
| Genistein | Chronic constriction sciatic nerve injury | C57BL/6J male mice | Subcutaneously/once a day for 11 days at doses of 1,3,7,5,15,30 mg/kg (in vitro and in vivo) | Restoration of mitochondrial GPX levels, and reduction of LPS-induced iNOS production | Reversal of mechanical allodynia and thermal hyperalgesia in a time and dose-dependent manner | [81] |
| Morin     | Chronic constriction injury | Male Sprague-Dawley rats | Oral/30 mg/kg for 14 days (in vitro and in vivo) | Reduced PARP overactivation and nitrite levels. Restored ATP and glutathione levels; repaired DNA damage | Reversed mechanical, chemical, and thermal hyperalgesia | [78] |
| Isoorientin| Chronic constriction injury | Adult, male specific pathogen free mice from ICR | Intragastric/7.5, 15 or 30 mg/kg per day | Ameliorated axonal swelling; prevented demyelination | Reduced hyperalgesia and allodynia | [80] |
| Quercetin and rutin | Oxaliplatin induced | male Swiss mice | i.v./nine injections of rutin (25, 50, and 100 mg/kg) or quercetin (25, 50, and 100 mg/kg) given twice a week (in vitro and in vivo) | Decreased LPS-induced iNOS expression | Inhibition of thermal and mechanical hyperalgesia | [56] |
| GSPE      | Chronic constriction injury | Wistar rats of either sex | Oral/100 and 200 mg/kg for 14 days (in vitro and in vivo) | Increased SOD and GSH | Attenuation of thermal hyperalgesia and mechanical allodynia | [79] |
| Silibinin | Oxaliplatin-induced neuropathy | Rat model of painful oxaliplatin-induced neuropathy | Silibinin (100 mg/kg), administered once a day, starting from the first day of oxaliplatin injection until the 20th | Prevention of oxidative damage | Antineuropathic effects | [90] |
8. Flavonoids: Promise, Applications, and Side Effects

CIPN is a multifactorial disease with various pharmacological mechanisms. Effective treatments should influence the mechanisms that contribute most to the symptoms. Damage to DRG neuronal cell bodies or axons contributes most strongly to CIPN symptom development. Likewise, flavonoids with the most success in animal models affect these areas by reducing peripheral sensitization of DRG neurons, modulating synaptic transmission at the spinal dorsal horn, and reducing mitochondrial damage in DRG neurons, among other mechanisms. However, how these mechanisms interact with and influence each other to cause symptoms still requires extensive investigation.

Moreover, pain results from interactions between central and peripheral mechanisms [93,94]. More information about central-peripheral interaction and central nervous system mechanisms of pain transmission (neuromodulators, neuroplasticity, central sensitization, and NTs) is needed to understand the pathophysiology of CIPN [50] entirely. Also, there are many clinical phenotypes of CIPN, and each requires a specific standardized treatment approach. For example, oxaliplatin and paclitaxel induce neuropathy through different mechanisms [93]. Adding a different complexity level, combinations of different anticancer drugs are used in treatment regimens [4,95].

Moreover, a specific flavonoid will alleviate some, but not all, symptoms. For example, 6-methoxyflavone [18] alleviates static and dynamic allodynia, whereas dimethoxyflavonol inhibits tactile allodynia [44], and quercetin decreases the thermal hyperalgesia and mechanical allodynia thresholds [41]. Therefore, since CIPN involves many symptoms, and specific flavonoids counteract specific anticancer drugs, combination therapies warrant further investigation [3].

It is essential to consider the concentrations of flavonoids that are useful in the treatment of CIPN. Flavonoids are present in relatively low concentrations in fruits and vegetables; these sources also contain a mixture of secondary plant metabolites such as vitamin C, folate, potassium, and fiber [96]. These secondary metabolites have known health benefits that cannot be replaced by a single compound (e.g., flavonoids) given as a dietary supplement [96]. Suppliers of flavonoid supplements recommend daily doses many times higher than those found in a flavonoid-rich diet. For example, quercetin is offered as a supplement with daily doses of 1 g or more [96], while its daily dietary intake is estimated to be between 10–100 mg [96].

Other issues to be considered in evaluating flavonoids as dietary supplements include drug interactions, trace element chelation, and thyroid status [97]. In vitro experiments indicate that purified flavonoids and flavonoid-rich extracts chelate iron, posing a risk for iron deficiency individuals. Flavonoids also interact with copper, manganese, and vitamin C [97,98]. They may exhibit antithyroid and goitrogenic activity. For example, quercetin and isoflavones inhibit iodothyronine deiodinase activity. High-dose isoflavones inhibit thyroid hormone biosynthesis, have estrogenic effects, and are goitrogenic [99,100]. Flavonoids may interfere with the absorption, tissue distribution, metabolism, and excretion of classical xenobiotics due to similar metabolic pathways. Notably, flavonoids interfere with all phase II enzymes, affecting the organism’s ability to detoxify endogenous and exogenous xenobiotics. For example, quercetin and kaempferol increase either the transcription or activity of the enzyme UDP-glucosyltransferase A1 [101].

Another vital factor to consider while reviewing in vitro studies is the effect of flavonoid distribution on local concentrations and drug interactions. For instance, quercetin and kaempferol inhibit CYP3A4 and, consequently, the metabolism of the $Ca^{2+}$ channel blockers nifedipine and felodipine in human liver microsomes at concentrations >10 $\mu$mol/L [102]. On the other hand, quercetin did not inhibit CYP3A4 metabolism of the statin simvastatin in pigs. A possible explanation for this is a lower hepatic concentration than observed in vitro [103].

Flavonoids (with C5 hydroxy and methoxy groups [104,105]) inhibit ABC transposers. The inhibition has positive consequences for poorly absorbed drugs but may result in drug toxicities for low therapeutic index drugs [106].
Given these side effects, it has been concluded by some that whole fruits and vegetables are more beneficial to health than any single plant constituent [107]. On the flip side, overexpression of ABC transporters is one of the major mechanisms of multidrug resistance encountered during chemotherapy treatments. Cancer cells overexpress the ABC transporter, which pumps out anticancer drugs before they can have a significant effect. Thus, flavonoids can reduce drug resistance and thereby enhance the efficacy of chemotherapy. Moreover, several studies suggest that flavonoids sensitize cancer cells to chemotherapy [108,109]. Quercetin especially has promise, combined with vincristine, to increase breast cancer treatment efficacy [110]. Therefore, the potential of flavonoids as adjuncts in chemotherapy creates an additional incentive to investigate further their potential in counteracting CIPN, especially in studies involving humans.

Flavonoids have potential as therapeutic agents for preventing CIPN; however, many questions remain unanswered due to the lack of flavonoid studies with human subjects; e.g., what serum concentration must be achieved to get a significant therapeutic effect? Can this concentration be achieved by supplementing the diet with flavonoid-rich foods, or are intravenous injections a must? According to Mongiovì et al., increasing citrus fruit intake poses its own problems in patients undergoing chemotherapy—their results showed a positive association between citrus fruit intake (rich in flavonoids) and neuropathic pain symptoms [111], which may indicate potential detrimental interactions between flavonoids and other substances in citrus fruits. However, other studies evaluating the effects of diet on CIPN did not show this association [112], and thus more studies are required to further elucidate the effects of citrus fruits on CIPN symptoms. Furthermore, due to flavonoids’ potential side effects, an extensive cost-benefit analysis in humans is needed to determine whether a flavonoid-based treatment should be explored further.

Translating results obtained from mouse models to humans presents challenges of its own. Sex, differences in social structure, and variations in genotype and neuroanatomy all influence pain pathways and pain perception [3,113]. Due to the differences in symptoms experienced by humans and mice [113], the effects of flavonoids on humans are expected to be highly variable. Another complicating factor is that, unlike patients with CIPN, most mice in these studies do not have cancer. Furthermore, murine chemotherapy delivery methods may not match clinical ones; additionally, the sex of the animals does not match clinical demographics—studies with animals use mostly male mice, but there are many female cancer patients as well [3]. Also, in animal models, only acute (experienced within the first six months after treatment), not chronic (occurring about two years following treatment), neuropathic pain is studied [3]. Thus, the elucidated mechanisms are related to the acute phase only, and treatment with flavonoids may not have the same effect on chronic neuropathic pain [3]. The mechanisms of chronic neuropathic pain warrant more research in animal models, especially in the context of flavonoids. The symptoms of chronic neuropathic pain vary from those of the acute phase. While the acute phase is marked by dysesthesia, paraesthesia, and hyperesthesia, chronic neuropathy is mainly associated with sensory ataxia, insomnia, anxiety, depression, cognitive and functional deficits, and fall risk [10,11,114]. So far, only one study has assessed the effects of flavonoids on symptoms specific to chronic neuropathy: Chtourou et al. investigated cisplatin exposure to acetylcholinesterase, ATPase, and oxidative stress biomarkers and the potential association this may have on behavioral performance in aged rats. The protective mechanisms of the flavonoid naringin were also studied. While cisplatin decreased enzymatic and non-enzymatic antioxidant activity in the hippocampus and raised levels of ROS, NO, MDA, and PCO, naringin reversed these effects and alleviated cisplatin-induced cognitive deficits (as seen by improved performance on the behavioral test administered) [115]. Flavonoids thus reverse anticancer drug-induced cognitive decline in chronic CIPN; in this light, their effects on the central nervous system merit further investigation. Also, flavonoids may hold promise in treating depression linked to chronic CIPN, since they are effective as antidepressants due to their antioxidant activity [116]. Furthermore, recent clinical results indicate that pediatric patients receiving azole antifungal treatment along with one-hour
infusions of vincristine develop less severe peripheral neuropathy than patients receiving only vincristine. Similar studies should be conducted with flavonoids, in which isolated or mixed flavonoids are delivered during chemotherapy treatment to decrease the onset and severity of symptoms [117].

In short, increasing evidence indicates that flavonoids may alleviate the symptoms of both acute and chronic CIPN, increase the efficacy of chemotherapy, and reduce the cognitive dysfunction that results from it; thus, their side effects, effects in humans, and mechanisms of action are priorities for further investigation.

9. Conclusions

Flavonoids hold great promise in the management of CIPN. Investigating the mechanisms through which flavonoids act furthers the understanding of peripheral neuropathy and offers new methods to overcome it. The burden of CIPN and the promise of flavonoids encourages future research into their actions in humans, as well as their therapeutic index and side effects.

Author Contributions: Conceptualization, M.S., B.A. and D.B.; methodology B.A. and M.S.; software, B.A. and M.S.; validation, B.A. and M.S.; formal analysis, B.A. and M.S.; investigation, B.A. and M.S.; resources, B.A. and M.S.; data curation, B.A. and M.S.; writing—original draft preparation, B.A. and M.S.; writing—review and editing, B.A., M.S. K.Z., A.L., P.K., and D.B.; visualization, B.A. and M.S.; supervision, D.B.; project administration, D.B.; funding acquisition, D.B. All authors have read and agreed to the published version of the manuscript.

Funding: This work was supported by a National Priorities Research Program grant (NPRP 11S-1214-170101; awarded to Dietrich Büsselberg, June 2019-Current) from the Qatar National Research Fund (QNRF, a member of Qatar Foundation). The statements made herein are solely the responsibility of the authors. The publication cost of this article was funded by the Weill Cornell Medicine–Qatar Distributed eLibrary.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Acknowledgments: All figures were produced using BioRender.

Conflicts of Interest: The authors declare no conflict of interest.

Abbreviations and Symbols

- GSPE: Grape Seed Proanthocyanidins
- CCI: Chronic Constriction Injury
- CIPN: Chemotherapy Induced Peripheral Neuropathy
- SNI: Sciatic Nerve Injury
- SNL: Sciatic Nerve Ligation
- PNL: Partial Nerve Ligation
- LPS: Lipopolysaccharide
- iNOS: Inducible Nitric Oxide Synthase
- MnSOD: Manganese Superoxide Dismutase
- mPTP: Mitochondrial Permeability Transition Pore
- GAPDH: Glyceraldehyde 3 phosphate Dehydrogenase
- GSH: Glutathione
- GPX: Glutathione Peroxidase
- TLR: Toll Like Receptor
- DRG: Dorsal Root Ganglion
- MAP: Mitogen Activated Protein
- GFAP: Glial Fibrillary Acidic Protein
- S1P: Sphingosine-1-phosphate
- HPETE: 5-hydroperoxyeicosatetraenoic acid
- VGCC: Voltage Gated Calcium Channels
SGC Satellite Glial Cells
ICW Intracellular Calcium Waves
ROS Reactive Oxygen Species
RNS Reactive Nitrogen Species
RCS Reactive Carbon Species
DPPH 2,2-diphenyl-1-picrylhydrazyl
SIRT1 Sirtuin 1
NT Neurotransmitter
PAR Protease Activated Receptor
NGF Nerve Growth factor
LKB-1 serine–threonine liver kinase B1
References

1. Bubalo, J. Chemotherapy-Induced Peripheral Neuropathy. *J. Hematol. Oncol. Pharm.* 2014, 4. Available online: http://jhoponline.com/jhop-issue-archive/2014-issues/september-vol-4-no-3/16203-chemotherapy-induced-peripheral-neuropathy (accessed on 25 March 2021).

2. American Cancer Society. What Is Peripheral Neuropathy? Available online: https://www.cancer.org/treatment/treatments-and-side-effects/physical-side-effects/peripheral-neuropathy/what-is-peripheral-neuropathy.html (accessed on 4 January 2021).

3. Sałat, K. Chemotherapy-induced peripheral neuropathy: Part 1—current state of knowledge and perspectives for pharmacotherapy. *Pharmacol. Rep.* 2020, 72, 486–507. [CrossRef]

4. Han, Y.; Smith, M.T.P. Pathobiology of cancer chemotherapy-induced peripheral neuropathy (CIPN). *Front. Pharmacol.* 2013, 4, 156. [CrossRef] [PubMed]

5. Lees, J.G.; Makker, P.G.; Tonkin, R.S.; Abdulla, M.; Park, S.B.; Goldstein, D.; Moalem-Taylor, G. Immune-mediated processes implicated in chemotherapy-induced peripheral neuropathy. *Eur. J. Cancer* 2017, 73, 22–29. [CrossRef]

6. Makker, P.G.S.; Duffy, S.S.; Lees, J.G.; Perera, C.J.; Tonkin, R.S.; Butovsky, O.; Park, S.B.; Goldstein, D.; Moalem-Taylor, G. Characterisation of Immune and Neuroinflammatory Changes Associated with Chemotherapy-Induced Peripheral Neuropathy. *PLoS ONE* 2017, 12, e0170814. [CrossRef]

7. Zajączkowska, R.; Kocot-Kępka, M.; Leppert, W.; Wrzosek, A.; Mika, J.; Wordliczek, J. Mechanisms of Chemotherapy-Induced Peripheral Neuropathy. *Int. J. Mol. Sci.* 2019, 20, 1451. [CrossRef]
32. Nilius, B.; Gudermann, T.; Jahn, R.; Lill, R.; Offermanns, S.; Petersen, O.H. The TRPA1 Channel in Inflammatory and Neuropathic Pain and Migraine. In Reviews of Physiology, Biochemistry and Pharmacology; Nilius, B.; Gudermann, T.; Jahn, R.; Lill, R.; Offermanns, S.; Petersen, O.H. Springer International Publishing: Cham, Switzerland, 2014; Volume 167, pp. 1–43. [CrossRef]

33. Materazzi, S.; Fusi, C.; Benemli, S.; Pedretti, P.; Patachini, R.; Nilius, B.; Prener, J.; Creminon, C.; Geppetti, P.; Nassini, R. TRPA1 and TRPV4 mediate paclitaxel-induced peripheral neuropathy in mice via a glutathione-sensitive mechanism. Pfliiger’s Archiv Die Gesamte Physiol. Menschen Tiere 2012, 463, 561–569. [CrossRef]

34. Old, E.A.; Nadkarni, S.; Grist, J.; Gentry, C.; Bevan, S.; Kim, K.-W.; Mogg, A.J.; Perretti, M.; Mancagio, M. Monocytes expressing CX3CR1 orchestrate the development of vincristine-induced pain. J. Clin. Investig. 2014, 124, 2023–2036. [CrossRef] [PubMed]

35. Chen, Y.; Yang, C.; Wang, Z. Proteinase-activated receptor 2 sensitizes transient receptor potential vanilloid 1, transient receptor potential vanilloid 4, and transient receptor potential ankyrin 1 in paclitaxel-induced neuropathic pain. Neuroscience 2011, 193, 440–451. [CrossRef] [PubMed]

36. Binshiot, A.M.; Wang, H.; Zimmermann, K.; Amaya, F.; Vardeh, D.; Shi, L.; Brenner, G.J.; Ji, R.-R.; Bean, B.P.; Woolf, C.J.; et al. Nociceptors Are Interleukin-1 Sensors. J. Neurosci. 2008, 28, 14062–14073. [CrossRef]

37. Jin, X. Acute p38-Mediated Modulation of Tetrodotoxin-Resistant Sodium Channels in Mouse Sensory Neurons by Tumor Necrosis Factor-α. Exp. Biol. Med. 2008, 233, 1729–1736. [CrossRef] [PubMed]

38. Opréd, A.; Kress, M. Involvement of the Proinflammatory Cytokines Tumor Necrosis Factor-α, IL-1β, and IL-6 But Not IL-8 in the Development of Heat Hyperalgesia: Effects on Heat-Evoked Calcitonin Gene-Related Peptide Release from Rat Skin. J. Neurosci. 2000, 20, 6289–6293. [CrossRef]

39. Chukyo, A.; Chiba, T.; Kambe, T.; Yamamoto, K.; Kawakami, K.; Taguchi, K.; Abe, K. Oxaliplatin-induced changes in expression of transient receptor potential potential channels in the dorsal root ganglion as a neuropathic mechanism for cold hypersensitivity. Neuropeptides 2018, 67, 95–101. [CrossRef] [PubMed]

40. Descoeur, J.; Pereira, V.; Pizzoccaro, A.; Francois, A.; Ling, B.; Maffre, V.; Couette, B.; Busserolles, J.; Courteix, C.; Noel, J.; et al. Oxaliplatin-induced cold hypersensitivity is due to remodelling of ion channel expression in nociceptors. EMBO Mol. Med. 2011, 3, 266–278. [CrossRef]

41. Gao, W.; Zan, Y.; Wang, Z.-J.; Hu, X.-Y.; Huang, F. Quercetin ameliorates paclitaxel-induced neuropathic pain by stabilizing mast cells, and subsequently blocking PKCe-dependent activation of TRPV1. Acta Pharmacol. Sin. 2016, 37, 1166–1177. [CrossRef] [PubMed]

42. Gui, Y.; Zhang, J.; Chen, L.; Duan, S.; Tang, J.; Xu, W.; Li, A. Icarinin, a flavonoid with anti-cancer effects, alleviates paclitaxel-induced neuropathic pain in mice. J. Clin. Investig. 2016, 129, 2511–2524. [CrossRef] [PubMed]

43. Nadipelly, V.; Nilius, B.; Gudermann, T.; Jahn, R.; Lill, R.; Offermanns, S.; Petersen, O.H. The TRPA1 Channel in Inflammatory and Neuropathic Pain and Migraine. In Reviews of Physiology, Biochemistry and Pharmacology; Nilius, B.; Gudermann, T.; Jahn, R.; Lill, R.; Offermanns, S.; Petersen, O.H. Springer International Publishing: Cham, Switzerland, 2014; Volume 167, pp. 1–43. [CrossRef]

44. Akbar, S.; Subhan, F.; Shahid, M.; Wadood, A.; Shahbaz, N.; Farooq, U.; Ayaz, M.; Raziq, N. 6-Methoxyflavanone abates paclitaxel-induced peripheral neuropathy in mice via a glutathione-sensitive mechanism. Pfliiger’s Archiv Die Gesamte Physiol. Menschen Tiere 2012, 463, 561–569. [CrossRef]

45. Jin, X. Acute p38-Mediated Modulation of Tetrodotoxin-Resistant Sodium Channels in Mouse Sensory Neurons by Tumor Necrosis Factor-α. Exp. Biol. Med. 2008, 233, 1729–1736. [CrossRef] [PubMed]

46. Leo, M.; Schmitt, L.-I.; Erkel, M.; Melnikova, M.; Thomale, J.; Hagenacker, T. Cisplatin-induced neuropathic pain is mediated by upregulation of N-type voltage-gated calcium channels in dorsal root ganglion neurons. Exp. Pain 2015, 26, 159–167. [CrossRef]

47. Illias, A.M.; Gist, A.C.; Zhang, H.; Kosturakis, A.K.; Dougherty, P.M. Chemokine CCL2 and its receptor CCR2 in the dorsal root ganglion contribute to oxaliplatin-induced mechanical hypersensitivity. J. Clin. Investig. 2008, 122, 1166–1177. [CrossRef]

48. Opred, A.; Kress, M. Involvement of the Proinflammatory Cytokines Tumor Necrosis Factor-α, IL-1β, and IL-6 But Not IL-8 in the Development of Heat Hyperalgesia: Effects on Heat-Evoked Calcitonin Gene-Related Peptide Release from Rat Skin. J. Neurosci. 2000, 20, 6289–6293. [CrossRef] [PubMed]

49. Gao, W.; Zan, Y.; Wang, Z.-J.; Hu, X.-Y.; Huang, F. Quercetin ameliorates paclitaxel-induced neuropathic pain by stabilizing mast cells, and subsequently blocking PKCe-dependent activation of TRPV1. Acta Pharmacol. Sin. 2016, 37, 1166–1177. [CrossRef] [PubMed]

50. Leo, M.; Schmitt, L.-I.; Jastrow, H.; Thomale, J.; Kleinschnitz, C.; Hagenacker, T. Cisplatin alters the function and expression of N-type voltage-gated calcium channels in the absence of morphological damage of sensory neurons. Mol. Pain 2017, 13. [CrossRef]

51. Xiao, W.; Boroujerdi, A.; Bennett, G.J.; Luo, Z.D. Chemotherapy-evoked painful peripheral neuropathy: Analgesic effects of gabapentin and effects on expression of the alpha-2-delta type-1 calcium channel subunit. Neuroscience 2007, 144, 714–720. [CrossRef]

52. Yamamoto, K.; Tsuboi, M.; Kambe, T.; Abe, K.; Nakatani, Y.; Kawakami, K.; Utsunomiya, I.; Taguchi, K. Oxaliplatin administration increases expression of the voltage-dependent calcium channel α2δ-1 subunit in the rat spinal cord. J. Pharmacol. Sci. 2016, 130, 117–122. [CrossRef]

53. Gold, M.S.; Gebhart, G.F. Nociceptor sensitization in pain pathogenesis. Nat. Med. 2010, 16, 1248–1257. [CrossRef]

54. Willis, W.D., Jr. Dorsal root potentials and dorsal root reflexes: A double-edged sword. Exp. Brain Res. 1999, 124, 395–421. [CrossRef] [PubMed]
55. Kushnir, R.; Cherkas, P.S.; Hanani, M. Peripheral inflammation upregulates P2X receptor expression in satellite glial cells of mouse trigeminal ganglia: A calcium imaging study. Neuropharmacology 2011, 61, 739–746. [CrossRef]

56. Azevedo, M.I.; Pereira, A.F.; Nogueira, R.B.; Rolim, F.E.; Brito, G.A.C.; Wong, D.V.T.; Lima-Júnior, R.C.P.; Ribeiro, R.D.A.; Vale, M.L. The Antioxidant Effects of the Flavanoids Rutin and Quercetin Inhibit Oxaliplatin-Induced Chronic Painful Peripheral Neuropathy. Mol. Pain. 2013, 9, 53. [CrossRef]

57. Matsumoto, M.; Inoue, M.; Haid, A.; Xie, W.; Ueda, H. Inhibition of Paclitaxel-Induced A-Fiber Hypersensitization by Gabapentin. J. Pharmacol. Exp. Ther. 2006, 318, 735–740. [CrossRef]

58. Li, Y.-Y.; Li, H.; Liu, Z.-L.; Li, Q.; Qiu, H.-W.; Zeng, L.-J.; Yang, W.; Zhang, X.-Z.; Li, Z.-Y. Alteration of STAT3-mediated CXCL12 up-regulation in the dorsal root ganglion contributes to oxaliplatin-induced chronic pain. Mol. Pain 2017, 13. [CrossRef] [PubMed]

59. Wang, J.; Zhang, X.-S.; Tao, R.; Zhang, J.; Liu, L.; Jiang, Y.-H.; Ma, S.-H.; Song, L.-X.; Xia, L.-J. Upregulation of CX3CL1 mediated by NF-κB activation in dorsal root ganglion contributes to peripheral sensitization and chronic pain induced by oxaliplatin administration. Mol. Pain 2017, 13. [CrossRef]

60. Li, Y.; Zhang, H.; Zhang, H.; Kosturakis, A.K.; Jawad, A.B.; Dougherty, P.M. Toll-Like Receptor 4 Signaling Contributes to Paclitaxel-Induced Peripheral Neuropathy. J. Pain 2014, 15, 712–725. [CrossRef] [PubMed]

61. Philipp, G.R.; Chiemprasert, T. Limited Hydrolysis of tRNA by Phosphodiesterase. Hoppe-Seyler’s Zeitschrift Physiol. Chem. 1975, 356, 1097–1104. [CrossRef]

62. Warwick, R.; Hanani, M. The contribution of satellite glial cells to chemotherapy-induced neuropathic pain. Eur. J. Pain 2012, 17, 571–580. [CrossRef]

63. Schmitt, L.; Leo, M.; Kutritz, A.; Kleinschnitz, C.; Hagenacker, T. Activation and functional modulation of satellite glial cells by oxaliplatin lead to hyperexcitability of sensory neurons in vitro. Mol. Cell. Neurosci. 2020, 105, 103499. [CrossRef]

64. Park, H.J.; Stokes, J.A.; Corr, M.; Yaks, T.L. Toll-like receptor signaling regulates cisplatin-induced mechanical allodynia in mice. Cancer Chemother. Pharmacol. 2013, 73, 25–34. [CrossRef] [PubMed]

65. Yoon, S.-Y.; Robinson, C.R.; Zhang, H.; Dougherty, P.M. Spinal Astrocyte Gap Junctions Contribute to Oxaliplatin-Induced Mechanical Hypersensitivity. J. Pain 2013, 14, 205–214. [CrossRef]

66. Zhang, H.; Yoon, S.-Y.; Zhang, H.; Dougherty, P.M. Evidence That Spinal Astrocytes but Not Microglia Contribute to the Pathogenesis of Paclitaxel-Induced Painful Neuropathy. J. Pain 2012, 13, 293–303. [CrossRef]

67. Stockstill, K.; Doyle, T.M.; Yan, X.; Chen, Z.; Janes, K.; Little, J.W.; Brande, K.; Lauro, F.; Giancotti, L.A.; Harada, C.M.; et al. Dysregulation of sphingolipid metabolism contributes to bortezomib-induced neuropathic pain. J. Exp. Med. 2018, 215, 1301–1313. [CrossRef] [PubMed]

68. Hu, L.-Y.; Zhou, Y.; Cui, W.-Q.; Hu, X.-M.; Mi, W.-L.; Chu, Y.-X.; Wu, G.-C.; Wang, Y.-Q.; Mao-Ying, Q.-L. Triggering receptor expressed on myeloid cells 2 (TREM2) dependent microglial activation promotes cisplatin-induced peripheral neuropathy in mice. Brain, Behav. Immun. 2018, 68, 132–145. [CrossRef]

69. Konishi, H.; Kiyama, H. Microglial TREM2/DAP12 Signaling: A Double-Edged Sword in Neural Diseases. Front. Cell. Neurosci. 2018, 12, 206. [CrossRef]

70. Huang, Z.-Z.; Li, D.; Ou-Yang, H.-D.; Liu, C.-C.; Liu, X.-G.; Ma, C.; Wei, J.-Y.; Liu, Y.; Xin, W.-J. Cerebrospinal Fluid Oxaliplatin Contributes to the Acute Pain Induced by Systemic Administration of Oxaliplatin. Anesthesiology 2016, 124, 1109–1121. [CrossRef] [PubMed]

71. Weber, A.; Wasiliew, P.; Kracht, M. Interleukin-1 (IL-1) Pathway. Sci. Signal. 2010, 3, cm1. [CrossRef] [PubMed]

72. Qin, B.; Li, Y.; Liu, X.; Gong, D.; Zheng, W. Notch activation enhances microglial CX3CR1/P38 MAPK pathway in rats model of vincristine-induced peripheral neuropathy. Neurosci. Lett. 2020, 715, 134624. [CrossRef] [PubMed]

73. Mannelli, L.D.C.; Pacini, A.; Micheli, L.; Femina, A.P.; Maresca, M.; Zannaradic, M.; Vannacci, A.; Gallo, E.; Bilia, A.R.; Caderni, G.; et al. Astragalus radix: Could it be an adjuvant for oxaliplatin-induced neuropathy? Sci. Rep. 2017, 7, srep42021. [CrossRef]

74. Kata, J.; Weng, H.-R.; Chen, J.-H.; Dougherty, P. Alteration of glutamate transporter expression in rats with paclitaxel-induced hyperalgesia. Neuroscience 2006, 138, 329–338. [CrossRef]

75. Weng, H.-R.; Aravindan, N.; Kata, J.; Chen, J.-H.; Shaw, A.D.; Dougherty, P.M. Spinal glutamate transporters downregulate in rats with taxol-induced hyperalgesia. Neurosci. Lett. 2005, 386, 18–22. [CrossRef]

76. Areti, A.; Yerra, V.G.; Naidu, V.; Kumar, A. Oxidative stress and nerve damage: Role in chemotherapy induced peripheral neuropathy. Redox Biol. 2014, 2, 289–295. [CrossRef] [PubMed]

77. Salvemini, D.; Little, J.W.; Doyle, T.; Neumann, W.L. Roles of reactive oxygen and nitrogen species in pain. Free. Radic. Biol. Med. 2011, 51, 951–966. [CrossRef]

78. Komirishetty, P.; Areti, A.; Sistla, R.; Kumar, A. Morin Mitigates Chronic Constriction Injury (CCI)-Induced Peripheral Neuropathy by Inhibiting Oxidative Stress Induced PARP Over-Activation and Neuroinflammation. Neurochem. Res. 2016, 41, 2029–2042. [CrossRef]

79. Kaur, G.; Bedi, O.; Sharma, N.; Singh, S.; Deshmukh, R.; Kumar, P. Anti-hyperalgesic and anti-nociceptive potentials of standardized grape seed proanthocyanidin extract against CCI-induced neuropathic pain in rats. J. Basic Clin. Physiol. Pharmacol. 2016, 27, 9–17. [CrossRef] [PubMed]

80. Zhang, G.; Liu, N.; Zhu, C.; Ma, L.; Yang, J.; Du, J.; Zhang, W.; Sun, T.; Niu, J.; Yu, J. Antinociceptive effect of isoorientin against neuropathic pain induced by the chronic constriction injury of the sciatic nerve in mice. Int. Immunopharmacol. 2019, 75, 105753. [CrossRef]
81. Valsecchi, A.E.; Franchi, S.; Panerai, A.E.; Sacerdote, P.; Trovato, A.E.; Colleoni, M. Genistein, a natural phytoestrogen from soy, relieves neuropathic pain following chronic constriction sciatic nerve injury in mice: Anti-inflammatory and antioxidant activity. *J. Neurochem.* 2008, 107, 230–240. [CrossRef] [PubMed]

82. Zhou, J. Targeting Microtubules for Cancer Chemotherapy. *Curr. Med. Chem. Agents* 2005, 5, 65–71. [CrossRef]

83. Staff, N.P.; Podratz, J.L.; Grassner, L.; Bader, M.; Paz, J.; Knight, A.M.; Loprinzi, C.L.; Trushina, E.; Windebank, A.J. Bortezomib alters microtubule polymerization and axonal transport in rat dorsal root ganglion neurons. *NeuroToxicology* 2013, 39, 124–131. [CrossRef]

84. Fukada, I.; Ito, Y.; Kobayashi, K.; Shibayama, T.; Takahashi, S.; Horii, R.; Akiyama, F.; lwase, T.; Ohno, S. The early onset of peripheral neuropathy might be a robust predictor for time to treatment failure in patients with metastatic breast cancer receiving chemotherapy containing paclitaxel. *PLoS ONE* 2017, 12, e0184322. [CrossRef] [PubMed]

85. McDonald, E.S.; Windebank, A.J. Cisplatin-Induced Apoptosis of DRG Neurons Involves Bax Redistribution and Cytochrome c Release But Not fas Receptor Signaling. *Neurobiol. Dis.* 2009, 39, 220–233. [CrossRef] [PubMed]

86. Cermak, R.; Wein, S.; Wolffram, S.; Langguth, P. Effects of the flavonol quercetin on the bioavailability of simvastatin in pigs. *J. Pharm. Sci.* 2001, 90, 2432–2440. [CrossRef] [PubMed]

87. Jaggi, A.S.; Singh, N. Mechanisms in cancer-chemotherapeutic drugs-induced peripheral neuropathy. *Toxicology* 2012, 291, 1–9. [CrossRef]

88. Canta, A.; Pozzi, E.; Carozzi, V.A. Mitochondrial Dysfunction in Chemotherapy-Induced Peripheral Neuropathy (CIPN). *Toxics* 2015, 3, 198–223. [CrossRef] [PubMed]

89. Doerge, D.R.; Sheehan, D.M. Goitrogenic and estrogenic activity of soy isoflavones. *Adv. Nutr.* 2011, 2, 8–14. [CrossRef]

90. Mokhtari, R.B.; Homayouni, T.S.; Baluch, N.; Morgatskaya, E.; Kumar, S.; Das, B.; Yeger, H. Combination therapy in combating chemotherapy-induced peripheral neuropathy. *Cancer* 2017, 122, 245–257. [CrossRef]

91. Egert, S.; Rimbach, G. Which Sources of Flavonoids: Complex Diets or Dietary Supplements? *Adv. Nutr.* 2011, 2, 1576–1587. [CrossRef] [PubMed]

92. Nair, A.K.; Dyson, L.J.; Thouvenot, P. Natural Polyphenols-Iron Interaction: Its Biological Importance. *Biochemistry* 2011, 50, 413–424. [CrossRef] [PubMed]

93. Dorsey, S.G.; Kleckner, I.R.; Barton, D.; Mustian, K.; O’Mara, A.; Germain, D.S.; Cavaletti, G.; Danhauer, S.C.; Hershman, D.L.; Hohmann, A.G.; et al. The National Cancer Institute Clinical Trials Planning Meeting for Prevention and Treatment of Chemotherapy-Induced Peripheral Neuropathy. *J. Natl. Cancer Inst.* 2019, 111, 531–537. [CrossRef] [PubMed]

94. Kleckner, I.R.; Zhang, J.; Touroutoglou, A.; Chanes, L.; Xia, C.; Simmons, W.K.; Quigley, K.S.; Dickerson, B.C.; Barrett, L.F. Evidence for a large-scale brain system supporting allostasis and interoception in humans. *Nat. Hum. Behav.* 2017, 1, 1–14. [CrossRef] [PubMed]

95. Mokhtarib, R.B.; Homayouni, T.S.; Baluch, N.; Morgatskaya, E.; Kumar, S.; Das, B.; Yeger, H. Combination therapy in combating cancer. *Oncotarget* 2017, 8, 38022–38034. [CrossRef]

96. Egert, S.; Rimbach, G. Which Sources of Flavonoids: Complex Diets or Dietary Supplements? *Adv. Nutr.* 2011, 2, 8–14. [CrossRef]

97. Hider, R.C.; Liu, Z.D.; Khodr, H.H. Metal chelation of polyphenols. *Methods Enzymol.* 2001, 335, 190–203. [CrossRef]

98. Anghileri, L.J.; Thouvenot, P. Natural Polyphenols-Iron Interaction: Its Biological Importance. *Biochimie* 2011, 93, 251–258. [CrossRef] [PubMed]

99. Flatters, S.J.; Bennett, G.J. Studies of peripheral sensory nerves in paclitaxel-induced painful peripheral neuropathy: Evidence for mitochondrial dysfunction. *Pain* 2006, 122, 245–257. [CrossRef]

100. Dorsey, S.G.; Kleckner, I.R.; Barton, D.; Mustian, K.; O’Mara, A.; Germain, D.S.; Cavaletti, G.; Danhauer, S.C.; Hershman, D.L.; Hohmann, A.G.; et al. The National Cancer Institute Clinical Trials Planning Meeting for Prevention and Treatment of Chemotherapy-Induced Peripheral Neuropathy. *J. Natl. Cancer Inst.* 2019, 111, 531–537. [CrossRef] [PubMed]

101. Mokhtarib, R.B.; Homayouni, T.S.; Baluch, N.; Morgatskaya, E.; Kumar, S.; Das, B.; Yeger, H. Combination therapy in combating cancer. *Oncotarget* 2017, 8, 38022–38034. [CrossRef]

102. Hider, R.C.; Liu, Z.D.; Khodr, H.H. Metal chelation of polyphenols. *Methods Enzymol.* 2001, 335, 190–203. [CrossRef]

103. Angilieri, L.J.; Thouvenot, P. Natural Polyphenols-Iron Interaction: Its Biological Importance. *Biochimie* 2011, 93, 251–258. [CrossRef] [PubMed]

104. Doerge, D.R.; Sheehan, D.M. Goitrogenic and estrogenic activity of soy isoflavones. *Environ. Heal. Perspect.* 2002, 110, 349–353. [CrossRef] [PubMed]

105. Milerová, J.; Červovská, J.; Zamrasil, V.; Bilek, R.; Lapčík, O.; Hampl, R. Actual levels of soy phytoestrogens in children correlate with normal laboratory parameters. *Clin. Chem. Lab. Med.* 2006, 44, 171–174. [CrossRef] [PubMed]

106. Walle, T. Induction of Human UDP-Glucuronosyltransferase UGT1A1 by Flavonoids—Structural Requirements. *Drug Metab. Dispos.* 2002, 30, 564–569. [CrossRef] [PubMed]

107. Miniscalco, A.; Lundahl, J.; Regardh, C.G.; Edgar, B.; Eriksson, U.G. Inhibition of dihydropyridine metabolism in rat and human liver microsomes by flavonoids found in grapefruit juice. *J. Pharmacol. Exp. Ther.* 1992, 261, 1195–1199. [CrossRef] [PubMed]

108. Cermak, R.; Wein, S.; Wolfgram, S.; Langguth, P. Effects of the flavonol quercetin on the bioavailability of simvastatin in pigs. *Eur. J. Pharm. Sci.* 2009, 38, 519–524. [CrossRef] [PubMed]

109. De Wet, H.; McIntosh, D.B.; Conseil, G.; Baubichon-Cortay, H.; Krell, T.; Jault, J.-M.; Daskiewicz, J.-B.; Barron, D.; Di Pietro, A. Sequence requirements of the ATP-binding site within the C-terminal nucleotide-binding domain of mouse P-glycoprotein: Structure-activity relationships for flavonoid binding. *Biochemistry* 2001, 40, 10382–10391. [CrossRef] [PubMed]

110. Hooijberg, J.H.; Broxtermann, H.J.; Heijn, M.; Fles, D.; Lankelma, J.; Pinedo, H.M. Modulation by (iso)flavonoids of the ATPase activity of the multidrug resistance protein. *FEBS Lett.* 1997, 413, 344–348. [CrossRef] [PubMed]

111. Cermak, R. Effect of dietary flavonoids on pathways involved in drug metabolism. *Expert Opin. Drug Metab. Toxicol.* 2007, 4, 17–35. [CrossRef] [PubMed]

112. Ross, J.A.; Kasum, C.M. Dietary flavonoids: Bioavailability, Metabolic Effects, and Safety. *Annu. Rev. Nutr.* 2002, 22, 19–34. [CrossRef] [PubMed]
108. Kim, D.H.; Khan, H.; Ullah, H.; Hassan, S.T.; Šmejkal, K.; Efferth, T.; Mahomoodally, M.F.; Xu, S.; Habtemariam, S.; Filosa, R.; et al. MicroRNA targeting by quercetin in cancer treatment and chemoprotection. *Pharmacol. Res.* 2019, 147, 104346. [CrossRef]

109. Sundaram, M.K.; Hussain, A.; Haque, S.; Raina, R.; Afroze, N. Quercetin modifies 5’CpG promoter methylation and reactivates various tumor suppressor genes by modulating epigenetic marks in human cervical cancer cells. *J. Cell. Biochem.* 2019, 120, 18357–18369. [CrossRef]

110. Wong, M.-Y.; Chiu, G.N. Liposome formulation of co-encapsulated vincristine and quercetin enhanced antitumor activity in a trastuzumab-insensitive breast tumor xenograft model. *Nanomed. Nanotechnol. Biol. Med.* 2011, 7, 834–840. [CrossRef]

111. Mongiovi, J.M.; Zirpoli, G.R.; Cannioto, R.; Sucheston-Campbell, L.E.; Hershman, D.L.; Unger, J.M.; Moore, H.C.F.; Stewart, J.A.; Isaacs, C.; Hobday, T.J.; et al. Associations between self-reported diet during treatment and chemotherapy-induced peripheral neuropathy in a cooperative group trial (S0221). *Breast Cancer Res.* 2018, 20, 146. [CrossRef] [PubMed]

112. Greenlee, H.; Hershman, D.L.; Shi, Z.; Kwan, M.L.; Ergas, I.J.; Roh, J.M.; Kushi, L.H. BMI, Lifestyle Factors and Taxane-Induced Neuropathy in Breast Cancer Patients: The Pathways Study. *J. Natl. Cancer Inst.* 2017, 109. [CrossRef]

113. Mogil, J.S. Animal models of pain: Progress and challenges. *Nat. Rev. Neurosci.* 2009, 10, 283–294. [CrossRef]

114. Bonhof, C.S.; Van De Poll-Franse, L.V.; Vissers, P.A.; Wasowicz, D.K.; Wegdam, J.A.; Révész, D.; Vreugdenhil, G.; Mols, F.; Poll-Franse, L.V. Anxiety and depression mediate the association between chemotherapy-induced peripheral neuropathy and fatigue: Results from the population-based PROFILES registry. *Psycho-Oncology* 2019, 28, 1926–1933. [CrossRef]

115. Chtourou, Y.; Gargouri, B.; Kebieche, M.; Fetoui, H. Naringin Abrogates Cisplatin-Induced Cognitive Deficits and Cholinergic Dysfunction Through the Down-Regulation of AChE Expression and iNOS Signaling Pathways in Hippocampus of Aged Rats. *J. Mol. Neurosci.* 2015, 56, 349–362. [CrossRef]

116. Hritcu, L.; Ionita, R.; Postu, P.A.; Gupta, G.K.; Turkez, H.; Lima, T.C.; Carvalho, C.U.S.; De Sousa, D.P. Antidepressant Flavonoids and Their Relationship with Oxidative Stress. *Oxidative Med. Cell. Longev.* 2017, 2017, 1–18. [CrossRef] [PubMed]

117. Van De Velde, M.E.; Kaspers, G.J.L.; Abbink, F.C.H.; Twisk, J.W.R.; Van Der Sluis, I.M.; Bos, C.V.D.; Heuvel-Eibrink, M.M.V.D.; Segers, H.; Chantrain, C.; Bosch, J.V.D.W.T.; et al. Vincristine-Induced Peripheral Neuropathy in Pediatric Oncology: A Randomized Controlled Trial Comparing Push Injections with One-Hour Infusions (The VINCA Trial). *Cancers* 2020, 12, 3745. [CrossRef] [PubMed]